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Abstract 
 
Signal transmission is a combination of electrical and chemical processes. Upon 
binding neurotransmitters, ligand-gated ion channels (LGICs) open to allow ion flux, 
which converts chemical signals to electrical signals. In this thesis, experiments in 
conjunction with computations are utilized to study the mechanism of the ligand-binding 
process. The powerful unnatural amino acid mutagenesis methodology provides a great 
tool to obtain a high-resolution image of the binding pocket at the chemical level.  
 
The target protein is a serotonin-gated ion channel, MOD-1. In order to 
understand the binding mechanism, we need to identify the non-covalent interactions 
responsible for binding. In Chapter 2, as a starting point, we prove that cation-π 
interactions between the agonist serotonin and Trp 226 in loop C of MOD-1 play a key 
role in binding the ligand. Surprisingly, this cation-π site in MOD-1 is different from that 
in 5-HT3R, although these two receptors both bind serotonin and are highly homologous. 
 
Next, efforts are made to obtain the entire orientation of the ligand inside the 
binding pocket. Upon binding, the agonist serotonin can potentially form hydrogen bonds 
with the MOD-1 receptor at three positions. If we can identify the hydrogen bonding 
pattern of serotonin inside the binding pocket, its orientation will be fixed at the chemical 
level.  
 
 viii
No crystal structure data are available for MOD-1. Therefore, in Chapter 3, a 
homology model of MOD-1 is built by using the template of acetylcholine binding 
protein (AChBP). We continue to dock the agonist into the binding pocket. The binding 
pattern from the model shows that there exist three hydrogen bonds between serotonin 
and the MOD-1 receptor, providing guidance for the ensuing experimental studies.  
 
In Chapter 4, a forward and reverse pharmacology strategy is applied to test the 
hydrogen bonding pattern of serotonin in MOD-1 experimentally. Both conventional and 
unnatural amino acid mutagenesis are used in conjunction with serotonin analogues. The 
results from these thorough structure-function studies confirm aspects of the hydrogen 
bond pattern described in the model.  
 
In Chapter 5, we apply another strategy called the tethered agonist approach to 
further probe the agonist-binding site. The tethered agonists are incorporated into the 
receptor so that the channel will be in the spontaneously opening state even without the 
addition of the natural agonist. Results from the tethered agonist experiments can provide 
further information on the ligand-binding pocket. This is another elegant example of the 
effectiveness of the unnatural amino acid mutagenesis methodology.   
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Chapter 1 
 
Introduction 
 2
1.1 Chemical Neurobiology 
 
Neurobiology is a challenging field in biological science due to its complexity. 
The ultimate goal of neurobiology is to understand how the human mind works to 
perceive, move, learn, and memorize.1 The human brain makes use of nerve cells called 
neurons and the connections between them to respond to the information obtained from a 
complicated network of sensory receptors. Even if we just do some simple numerical 
estimations of the human brain, we will find that understanding the brain seems daunting. 
A human brain has roughly 1011 neurons, which can be divided into at least 1000 
different types. Communication among the vast majority of neurons occurs through 
minute clefts as small as 20–40 nm called synapses (Figure 1.1). A neuron can form 
thousands of synapses with other neurons, which will yield over 100 trillion synapses in 
the brain.2  
Signal transmission is a combination of electrical and chemical processes. An 
electrical impulse can travel along the long axon of a neuron. When this impulse reaches 
the axon terminal, vesicles in the pre-synaptic neuron release small chemicals called 
neurotransmitters, such as acetylcholine and serotonin. Neurotransmitters will diffuse 
very quickly across the tiny synapse and bind to the corresponding post-synaptic 
receptors, such as G-protein-coupled receptors (GPCRs) and ion channels. This binding 
behavior leads to a change of the local electrical activity, which can be transmitted to 
induce downstream neurotransmitter release for further communication between neurons. 
The post-synaptic neuroreceptors, which are membrane proteins, play important roles in 
regulating the signal transmission process, and will be discussed in detail in the following. 
 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Neurons and signal transmission through synapses. Neurotransmitters from a 
pre-synaptic nerve terminal diffuse across the synapse and bind to corresponding post-
synaptic receptors such as GPCRs and ion channels.  
 
 
To understand how neuroreceptors function seems difficult due to their structural 
complexity. Fortunately, with the development of structural biology, molecular biology, 
and electrophysiology, it is now possible to perform a thorough structure-function study 
on neuroreceptors at the molecular level. Evidently, to understand the mechanism by 
which the receptors work, we need to gain information on the following three aspects. 
First, high-resolution structural data need to be obtained. A few decades ago, it 
was thought that it was impossible to determine crystal structures of integral membrane 
proteins due to the difficulty of obtaining their crystals. With the recent advance of 
crystallography, now many membrane proteins have been successfully crystallized at 
high resolution.3 The breakthrough was marked by two high-resolution ion channel 
crystal structures in 1998.4, 5 The structural data will undoubtedly benefit the functional 
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study of the proteins although high-throughput crystallography methods still should be 
further developed.  
Second, the structures of neuroreceptors need to be modified to provide further 
insights into their functions. Recombinant DNA technology has revolutionized 
biochemistry since its appearance in the 1970s. Together with the invention of the 
polymerase chain reaction in the 1980s, in principle, according to our needs, we can 
modify the cDNA that encodes the target protein, and obtain the desired mutant protein 
after translation. Therefore, now we can change the structure of neuroreceptors easily at 
the molecular level. A single amino acid mutation can be introduced by site-directed 
mutagenesis; a chimera protein can also be built by cutting and ligating several regions of 
interest. The neuroreceptor proteins can be expressed in different systems, such as 
Xenopus oocytes and human embryonic kidney (HEK) cells. 
Finally, we need a sensitive functional assay to monitor the effect that the 
structural changes cause. In the case of neuroreceptors, the technique of 
electrophysiology is utilized. The voltage clamp technique, fully developed by Hodgkin 
and Huxley in the 1950s,6 enables the whole cell recording of currents during channel 
activation. Furthermore, the patch clamp technique was invented by Neher and Sakmann 
in the 1970s7 and further refined in early 1980s,8 which can be used to record single 
channel activity. These electrophysiology tools provide a powerful method to measure 
channel activity in real time under relatively physiological conditions.  
Molecular neurobiology is developing very quickly, and the mechanism of how 
neuroreceptors work is being disclosed from structure-function studies as well as the 
emergence of high-resolution structures.   
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Recently, the field of chemical biology grasped the attention of many chemists 
and biologists. From the view of the editors of Nature Chemical Biology, “Chemical 
Biology has emerged as a field grounded in technological advances brought about by the 
close collaboration of chemists and biologists. Using diverse experimental and theoretical 
techniques, chemical biologists have tackled challenging problems in biology, ranging 
from cellular signaling to drug development and neurobiology.”9 
Here we focus on chemical biology of neuroreceptors. We continue the efforts of 
neurobiology from a molecular level to a chemical level. Therefore, the term chemical 
neurobiology is used here to describe a chemical-scale study on the molecules of the 
nervous system, namely, neuroreceptors.10  
To change the atomic structure of neuroreceptors, conventional site-directed 
mutagenesis is restricted to the twenty natural amino acids. Systematic study of the role 
of one specific amino acid is limited by this method.  Fortunately, unnatural amino acids 
can be incorporated into neuroreceptors by using the in vivo nonsense suppression 
methodology.11 This method provides much greater structural diversity and delivers very 
subtle modifications to proteins. Unnatural amino acid mutagenesis combined with 
electrophysiology recording allows us to perform a chemical-scale study on 
neuroreceptors.  
 
1.2 Incorporation of Unnatural Amino Acids into Proteins 
 
Most of the current studies on unnatural amino acid methodology focus on the 
site-specific incorporation of one unnatural amino acid into a protein in vitro or in vivo.12 
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These studies can be categorized into two fields: first, chemically acylated suppressor 
tRNAs are used; second, the twenty-first aminoacyl-tRNA synthetase is engineered to 
incorporate unnatural amino acids.  
 
In the first field, the unnatural amino acid is introduced into the expression system 
after chemical acylation to an in vitro transcribed suppressor tRNA. This suppression 
method has been well-developed since its introduction in the 1980s.13-15 It is illustrated in 
Figure 1.2. The chemical acylation process of an unnatural amino acid to an in vitro 
transcribed suppressor tRNA is shown in Figure 1.3. An unnatural amino acid, which is 
chemically acylated to a suppressor tRNA, is transferred to the site of interest, which is 
encoded by a proper codon. For an in vitro application, translation mixtures from E. coli 
and rabbit reticulocyte can be used. For an in vivo application, both mRNA and tRNA 
can be injected into the Xenopus oocyte expression system for translation. Recently, 
unnatural amino acids have been site-specifically expressed into receptors expressed in 
mammalian cells.16 The main limitation of this method is that the aminoacylated tRNA is 
consumed as a stoichiometric reagent. Therefore, the translated protein amount is limited 
by the amount of the aminoacylated tRNA that can be introduced into the translation 
system.17 One critical requirement of this method is that the suppressor tRNA must not be 
aminoacylated by any of the endogenous aminoacyl-tRNA synthetases (aaRSs), i.e., the 
suppressor tRNA should be orthogonal to endogenous aaRSs. A variety of suppressor 
tRNAs and their corresponding codons have been developed.  
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(b) 
(a) 
 
 
Figure 1.2 The nonsense suppression methods in vitro and in vivo. (a) The principle of 
nonsense suppression method. (b) The application in in vitro and in vivo systems.  
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Figure 1.3 Chemical acylation of an unnatural amino acid to an in vitro transcribed 
suppressor tRNA. The red dot represents an unnatural amino acid.  
 
 
The use of different expression systems led to the development of a variety of 
suppressor tRNAs. In 1989, the Schultz group originally used a yeast tRNAPhe (CUA) 
suppressor in the E. coli translation system based on the idea that yeast tRNAs are not 
recognized by E. coli aminoacyl tRNA synthetases.15 Later, they generated an E. coli 
tRNAAsn-derived suppressor in the E. coli translation system.18 This new suppressor 
showed a significant improvement in suppression efficiency. In early studies, Chamberlin 
and co-workers developed an E. coli tRNAGly-derived suppressor. They used this 
suppressor in a rabbit reticulocyte expression system.14 Dougherty and co-workers tried 
to generate an optimal suppressor tRNA for the oocyte expression system.19 At first, 
tRNA-MN3, a suppressor modified from the yeast tRNAPhe (CUA), was used.11 However, 
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in some cases natural amino acids were unexpectedly inserted, probably due to the 
reacylation of chemically acylated tRNA-MN3 by endogenous aaRSs. To overcome this, 
a new nonsense suppressor tRNA based on tRNAGln(CUA) from the eukaryote 
Tetrahymena thermophila was designed.20 A major modification was to mutate U73 to G 
to reduce recognition by the oocyte's endogenous glutamine acyltransferase. This new 
suppressor tRNA significantly improved the suppression efficiency. 
 
 
 
 
 
 
  
 
C U A
G A U
tRNA
5’3’
mRNA
Figure 1.4 Codons used in response to the aminoacylated suppressor tRNAs to 
incorporate unnatural amino acids into proteins. (a) Amber codon. An amber codon is 
recognized by aa-tRNA containing a CUA anticodon. (b) Four-base codon. CGGG is 
recognized by aa-tRNA containing a CCCG anticodon. (c) Unnatural base pairs yAG-
CUs as the codon-anticodon pair. The red dots represent unnatural amino acids. 
   
 
In response to the aminoacylated suppressor tRNA, several kinds of codons are 
used, such as stop codons, four-base codons, and unnatural bases (Figure 1.4).21  
 
Amber (UAG) suppressors have been the most widely used both in vitro and in 
vivo.11, 15 Chamberlin and co-workers reported that opal (UGA) and ochre (UAA) 
suppressors gave reasonably good suppression levels in rabbit reticulocyte lysate.22 
C C C G
G G G C
tRNA
5’3’
mRNA C U s
G A y
tRNA
5’3’
mRNA
(a) (b) (c) 
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However, Schultz and co-workers reported that an opal suppressor showed a high level of 
readthrough in E. coli.18 Recently, RajBhandary and co-workers reported that an ochre 
suppressor tRNA was imported into mammalian cells.23 Amber (UAG) suppressors have 
been successfully applied in different expression systems. Dougherty and co-workers 
have been using oocytes as the translation system to perform structure-function studies in 
vivo.19 In vitro protein synthesis is performed in rabbit reticulocyte lysate, wheat germ 
extract, or bacterial S-30 extract.24, 25 Due to the competition of release factors in these 
translation systems, the nonsense suppressor tRNAs have relatively low efficiency. The 
use of an E. coli S-30 extract deficient in release factor 1 improves the suppression 
efficiency.26 With the development of the RNAi technique, it is possible to remove 
release factor 1 in the translation system to improve the suppression efficiency.27  
Recently, four-base codons and corresponding frameshift suppressor tRNAs have 
been developed in vitro.28, 29 This frameshift suppression method can avoid the 
competition between the suppressor tRNA and endogenous release factors. It has also 
demonstrated higher suppression efficiency than nonsense suppression. Furthermore, the 
diversity of the four-base codons can be used to incorporate multiple unnatural amino 
acids into a protein. Using a set of two four-base codons, AGGU and CGGG, the Sisido 
group successfully incorporated two different unnatural amino acids into streptavidin in E. 
coli.30 Later they utilized another set of two four-base codons, CGGG and GGGU, to give 
a higher suppression efficiency.31 Their work has been reviewed.28 The four-base codons 
they used are summarized in Figure 1.5. Among the reported four-base codons, CGGG, 
GGGU, and CUCU have higher frameshift suppression efficiency. Further investigation 
of five-base codons in vitro32 and four-base codons in vivo33, 34 also appeared. The limits 
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of codon and anticodon size were explored and it was found that three to five bases 
codons could be well-tolerated by the translation machinery. 35  
 
 
 
Figure 1.5 Four-base codons assigned to unnatural amino acids. Adapted from Ref28. 
 
 
Another strategy is to choose unnatural base pairs as codon/anticodon pairs. In 
collaboration with the Benner group, the Chamberlin group successfully applied an isoC 
and isoG unnatural base pair in the codon-anticodon loops for unnatural amino acid 
incorporation.36 However, both the tRNA and mRNA containing unnatural base pairs 
needed to be synthesized by chemical methods. Recently, another unnatural base pair, y 
(pyridine-2-one) and s (2-amino-6-(2-thienyl)purine), was used with high efficiency.37 
The mRNA containing y can be transcribed from corresponding DNA template, although 
the tRNA containing s needs to be synthesized. This strategy could be very useful in 
multiple unnatural amino acid incorporation if both mRNA and tRNA containing 
unnatural base pairs can be easily obtained through transcription.  
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In the second field, efforts have been made to engineer the 21st aminoacyl-tRNA 
synthetase-suppressor tRNA pairs. Although the 21st aaRS-tRNA pairs are intriguing, it 
was demonstrated to be extremely difficult to introduce an unnatural amino acid using 
this method.38 The 21st aaRS-tRNA pairs must meet two critical requirements. First, the 
suppressor tRNA must not be aminoacylated by any of the endogenous aminoacyl-tRNA 
synthetases. Second, the aminoacyl-tRNA synthetase must aminoacylate the suppressor 
tRNA with the desired unnatural amino acid but no other tRNAs in the cell. The most 
striking progress in this field was the successful incorporation of O-methyl-L-tyrosine 
into proteins in E. coli with high fidelity (greater than 99%).39 In this experiment, a 
general and systematic selection approach was developed to generate mutant synthetases 
that could selectively aminoacylate their cognate orthogonal tRNA with unnatural amino 
acids. Later, some other efficient selection methods were further developed.40, 41 To date, 
over thirty novel amino acids have been successfully incorporated into proteins in E. 
coli.42 However, challenges still exist for the incorporation of unnatural amino acids that 
differ significantly from their natural counterparts.  
 
Thus far, the nonsense suppression method has been the most widely used.  Since 
report of this method, over 100 amino acids have been site-specifically incorporated into 
dozens of proteins including soluble and membrane proteins of virtually any size except 
D-amino acids or β-amino acids.12 The structures of incorporated unnatural amino acids 
are shown in Figure 1.6. They were applied to study ligand-binding sites, protein 
conformational changes, and protein-protein interactions.  
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Figure 1.6 Structures of unnatural amino acids incorporated into proteins using nonsense 
suppression method. Adapted from Ref12. 
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In our case, we are interested in applying this nonsense suppression method to 
study neuroreceptors, more specifically, ligand-gated ion channels. Xenopus oocytes are 
excellent expression systems for ion channels.43 A chemical-scale structure-function 
study can be fulfilled by this powerful unnatural amino acid mutagenesis method.44   
 
 
1.3 The Cys-Loop Superfamily of Ligand-Gated Ion Channels and Insights from 
the Crystal Structure of Acetylcholine Binding Protein (AChBP) 
 
Ion channels are membrane proteins.45 They exist in prokaryotic and eukaryotic 
organisms, and perform diverse functions. Channels have families: they can be ligand-
gated or voltage-gated. Upon stimulation, ion channels open and transport ions across the 
surface membrane, thus delivering the corresponding signals.  
Malfunction of ion channels can lead to serious problems in the cell, and can 
cause ion channel diseases called channelopathies.46 Channelopathies can arise from 
different pathways. The most common sources are due to mutations in the ion channel 
proteins themselves. Mutations may make the ion pore more difficult to open, or 
mutations may lead to misfolding of the proteins, therefore reducing the surface 
expression of the ion channels. We are most interested in the Cys-loop superfamily of 
ligand-gated ion channels (LGICs). The common diseases related to the Cys-loop 
superfamily of LGICs are summarized in Table 1.1.47 The study of these ion channels 
will benefit the treatment of many diseases, such as Alzheimer’s disease, Parkinson’s 
disease, and epilepsy.  
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Table 1.1 The common diseases associated with the Cys-loop superfamily of LGICs.a 
 
a Abbreviations: NR, not reported.  
 
 
 As a major class of LGICs, the Cys-loop superfamily is characterized by the 
cysteine loop located in the large extracellular N-terminus.47-49 The Cys-loop is separated 
by 13 amino acids. The Cys-loop superfamily includes the excitatory cation channels and 
the inhibitory chloride channels. Cation channels include nicotinic acetylcholine 
(nAChR),50, 51 serotonin type 3 (5-HT3R; to date three subunits have been identified, 
namely 5-HT3A, 5-HT3B, and 5-HT3C),52 zinc-activated (ZAC),53 and excitatory GABA-
gated (EXP-1)54 receptors. Inhibitory channels include GABAA55, 56 and GABAC,57 
glycine,58, 59 MOD-1,60 and glutamate-gated chloride (GluCl)61 receptors. To date, EXP-1, 
MOD-1 and GluCl receptors have been found only in invertebrates.   
  
Upon stimulation, neurotransmitters diffuse across the synapse within a few 
microseconds and bind to the corresponding ion channels. This binding behavior will 
induce a conformation change allosterically, and open the ion pore. After a few 
milliseconds, the channels will return to the closed state again. To understand how ion 
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channels function, we need to study the neurotransmitter binding behavior and the gating 
mechanism.  
 
 
 
(b) (a) 
 
 
 
 
 
 
 
Figure 1.7 Structural features of nAChR. (a) Subunit arrangement. (b) Subunit topology, 
with four transmembrane helices (M1- M4) and a large extracellular N-terminal domain.  
 
 
The Cys-loop superfamily of ligand-gated ion channels shares some common 
structural characteristics. Most of our knowledge on the structures of the Cys-loop 
superfamily comes from nAChR.62 The structure of nAChR was observed at the 9 Å and 
later at 4.6 Å resolution by the Unwin group using cryoelectron microscopy.63, 64 
Recently, the structure was further refined to 4 Å resolution.65, 66 The nAChR is 
pentameric, composed of two α subunits, one β subunit, one γ subunit, and one δ subunit 
(Figure 1.7). Each subunit has four transmembrane helices, M1–M4, with M2 lining the 
interior of the pore. A large extracellular N-terminus contains the ligand-binding site. 
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(a) (b) 
 
  
 
 
 
Figure 1.8 Ligand-binding sites of nAChR. (a) One ligand-binding site between two 
adjacent subunits: α and γ. Loop A to loop F are important in binding the ligand. (b) The 
key aromatic residues around the ligand-binding site. 
 
 
The resolution of the 4 Å nAChR structure is not high enough to give information 
on the ligand-binding sites at the atomic level. Photoaffinity labeling, radioligand binding, 
and mutational studies were used to study the ligand-binding sites of nAChR. The two 
binding sites lie between subunit interfaces: one between α and γ; the other between α 
and δ. Several loops (loop A to loop F), which are different regions of sequence, define 
the ligand-binding sites. A large number of aromatic residues are present in the loops 
(Figure 1.8).62  
In 2001, the soluble acetylcholine binding protein (AChBP) from the snail 
Lymnaea stagnalis (Ls-AChBP), which is highly homologous to the extracellular domain 
of the Cys-loop superfamily, was successfully crystallized at 2.7 Å resolution by the 
Sixma group.67, 68 AChBP is a homopentamer; each subunit shares about 20% sequence 
identity with the Cys-loop superfamily. The core structure of each subunit is ten β-
strands, which are connected by loops or turns. The key loops (loop A to loop F), as well 
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as the key aromatic residues, which are important in binding the ligand, are well-
conserved (Figure 1.9).  
 
  
 
 
 
 
 
 
 
            (a)                (b) 
Figure 1.9 Crystal structure of AChBP. (a) Homopentamer of AChBP. The key loops are 
conserved between two subunits interface. (b) The key aromatic residues in AChBP near 
the binding sites.  
 
 
 Later, the crystal structures of AChBP with the agonist nicotine or 
carbamylcholine bound were resolved at high resolution.69 It was found that nicotine 
formed a hydrogen bond with the carbonyl group of Trp143 in AChBP. This hydrogen 
bond was proven by an unnatural amino acid study using an α-hydroxy acid in nAChR.70  
Recently, the crystal structures of AChBP from different species (Bulinus truncates and 
Aplysia californica) with or without ligands bound were solved.71, 72 Comparison of these 
structures with those from Ls-AChBP will help us improve the structure-function study.  
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The appearance of AChBP greatly stimulatd the research field of the Cys-loop 
ligand-gated ion channels in several aspects.  
 
First, this AChBP structure confirmed all the previous experimental data on the 
ligand-binding domains of nAChR. This high-resolution structure showed the 
effectiveness of the loop model for binding, and gave details on the binding pockets. It 
gave the structural basis for further study of the binding of agonists, antagonists, and 
other toxin molecules, and should benefit drug design. 
Second, with the development of computational chemistry, the AChBP can serve 
as a reliable template to build homology models for the Cys-loop superfamily. The 
homology models will give valuable insights into the whole Cys-loop superfamily.  
Third, although AChBP does not contain the transmembrane domains and cannot 
gate, the structural information can be used to study the coupling between binding and 
gating. It is clear from the structure that loop 5 is near the ligand-binding site and that 
loop 2 and loop 7 regions are close to the transmembrane domains. The Auerbach group 
proposed a conformational wave model for gating.73 They performed single channel 
studies on the ligand-binding sites, loop 5, loop 2 and loop 7, the M2-M3 linker, and the 
ion pore regions of nAChR. It was proposed that after binding, loop 5 moved first, and 
loop 2/loop 7 domains moved afterwards. This stepwise movement was termed 
conformational wave, which was then extended to the M2-M3 linker and the ion pore 
region.74 Harrison and co-workers focused on the coupling between loop 2/loop 7 regions 
and the M2-M3 linker in the α1 subunit of GABAA receptors.75 They performed charge-
reversal double mutations and proposed that electrostatic interactions between Asp 149 
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in loop 7 and Lys 279 in the M2-M3 linker provided a potential mechanism for the 
coupling process. However, Unwin’s nAChR structure suggested that hydrophobic 
interactions between Val 44 in loop 2 and residues in the M2-M3 linker contributed to 
the coupling process.66 Now it seems that the coupling between loop 2/loop 7 regions and 
the M2-M3 linker is complicated, and cannot be elucidated only by the simple 
electrostatic interactions or hydrophobic interactions. The Sine group studied the initial 
coupling of binding to gating in nAChR. Using simulation and intrinsic tryptophan 
fluorescence, it was shown that after binding, loop C moved inward to occlude the 
entrance of the binding pockets.76 Beyond the initial binding pockets, using single 
channel recording, the Sine group showed that upon binding of the agonist, Tyr 190 in 
loop C moved inside the binding pocket. This movement could destroy a salt bridge 
between Lys 145 in β-strand 7 and Asp 200 in β-strand 10 and loosen their contact. It 
was proposed that this process is involved in initiating the coupling of binding to 
gating.77 The coupling process of the Cys-loop receptors is still an active research field. 
The actual coupling mechanism remains to be elucidated.  
 
The structure of the transmembrane domains of nAChR was recently solved at 
4.0 Å resolution.66 It showed that hydrophobic interactions between Leu 251 in the M2 
region  contributed to the actual gate of the ion pore, which was consistent with previous 
mutational gating studies.78 Using knowledge from the crystal structure of AChBP, the 
Unwin group built the structure of the whole nAChR at 4.0 Å resolution (Figure 1.10).65 
This structure will benefit the study of the whole Cys-loop receptor superfamily, 
especially on the gating process.   
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Figure 1.10 Structure of the whole receptor of nAChR. (a) View from the synaptic cleft.  
(b) A single α subunit of a side view. Adapted from Ref65. 
 
 
1.4 Summary 
 
We aim to perform a thorough structure-function study on the ligand-binding site 
of the Cys-loop superfamily of the LGICs. From the viewpoint of a chemist, we would 
like to obtain a detailed map of the ligand in the binding pocket. It is evident that non-
covalent interactions contribute to directing the agonist to the binding pocket. We want to 
know the specific orientation of the agonist in the binding pocket and what kind of non-
covalent interactions play the major role.  
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In this thesis, our target protein is the MOD-1 receptor.60 The MOD-1 receptor 
was discovered in 2000. It is a serotonin-gated chloride channel that modulates 
locomotory behavior in the nematode Caenorhabditis elegans. The gene mod-1 is 
responsible for modulation of locomotion; therefore, the protein is termed MOD-1. It 
belongs to the Cys-loop superfamily of ligand-gated ion channels (LGICs). This receptor 
is unique in that its agonist, serotonin (5-hydroxytryptamine or 5-HT), is the agonist of 
excitatory 5-HT3 receptors while its anion selectivity is characteristic of inhibitory 
receptors such as the GABAA receptor and glycine receptor.  
We will use chemistry to study the ligand-binding site of MOD-1. A high-
resolution crystal structure of AChBP is available. Computational chemistry can be used 
to build a homology model of MOD-1 using the AChBP template. We proceed to dock 
the agonist into the binding pocket. This modeling study is presented in Chapter 3. The 
binding pattern from the model can give us insights and guidance for experimental study.  
Unnatural amino acid mutagenesis is a powerful tool to modify the structure of 
the protein at the chemical level. Systematic perturbations can be introduced at a specific 
amino acid. Therefore, specific non-covalent interactions, such as hydrogen bonding, 
hydrophobic interactions, and cation-π interactions can be probed. In Chapter 2, we prove 
that cation-π interactions between the agonist serotonin and Trp 226 in loop C of MOD-1 
play a key role in binding the ligand. Surprisingly, this cation-π site in MOD-1 is 
different from that in 5-HT3R although these two receptors both bind serotonin and are 
highly homologous. In Chapter 4, we further show that hydrogen bonds between 
serotonin and Gln 228 and Asn 223 in MOD-1 are also important in the binding process.  
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In Chapter 5, we apply another strategy called the tethered agonist approach to 
further probe the agonist binding site. The tethered agonists are incorporated into the 
protein so that the channel will be in the spontaneously open state even without the 
addition of the natural agonist. This is another elegant example of the effectiveness of the 
nonsense suppression method.  
 
In summary, we perform a chemical-scale study on the ligand-binding site of a 
serotonin-gated ion channel, MOD-1. Therefore, it is possible to perform chemical 
neurobiology on this extremely complicated system. Progress in this challenging field is 
being made with the development of structural biology, molecular biology, 
electrophysiology, organic synthesis, and computational modeling. This is an example in 
the developing field of chemical biology, which will benefit drug design and human 
health.  
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Chapter 2 
 
Different Cation-π Sites at Two Homologous Serotonin 
Receptors, MOD-1 and 5-HT3R 
 31
2.1 Introduction 
 
 The cation-π interaction is an important non-covalent binding force in structural 
biology.1-3 Our initial goal is to explore new ion channel systems to confirm that this non-
covalent interaction is general. 
Previous studies on the nicotinic acetylcholine receptor (nAChR) show that a 
cation-π interaction exists between the agonist acetylcholine (for the molecular structure, 
see Figure 2.1) and Trp 149 in the α subunit of nAChR.4 This cation-π interaction is 
further supported by the crystal structure of acetylcholine binding protein (AChBP) 
(Figure 1.9).5 The nAChR is the most well-studied and serves as the prototype of the 
whole Cys-loop superfamily of LGICs.  
MOD-1 and 5-HT3R are highly homologous in the ligand-binding domains. They 
both bind serotonin (for the molecular structure, see Figure 2.1) for activation. Trp 183 in 
5-HT3R, a homolog of Trp 149 in nAChR, forms a strong cation-π interaction with 
serotonin.6 In this chapter, we continue our effort to identify the cation-π site of serotonin 
in the MOD-1 receptor.  
 
 
 
 
 
       (a)     (b) 
Figure 2.1 Molecular structures of serotonin and acetylcholine. (a) Serotonin. (b) 
Acetylcholine. 
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2.1.1 Cation-π Interactions 
  
The cation-π interaction is an important general force in structural biology.7 
Numerous studies have shown that the cation-π interaction is important in biological 
recognition.2, 8 In evaluating drug-receptor interactions, the cation-π interaction should be 
considered along with other non-covalent interactions.1 
  
Cations bind to the π-face of an aromatic ring through a strong non-covalent force 
termed the cation-π interaction (Figure 2.2 (a)). The simple model of benzene as the 
aromatic ring qualitatively shows that this interaction arises from the quadrupole moment 
of benzene, which will interact with properly positioned charges through electrostatic 
forces (Figure 2.2 (b)).  
 
 
 
 
Figure 2.2 The cation-π interaction. (a) A generic cation interacting with benzene. (b) 
Quadrupole moment of benzene. 
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 In the biological context, the aromatic side chains of Phe, Tyr, and Trp participate 
in cation-π interactions. Their cation-π binding energies were evaluated by a simple 
model system of a sodium cation with a series of aromatic systems using the Hartree-
Fock method at the 6-31G** level.9 The calculated numbers were used to correlate with 
the experimental results.4 
Recently, some purely computational efforts have been made to explore more 
diverse systems to study cation-π interactions using high-level MP2 or DFT methods. 
Different cations, such as Li+, K+, alkaline earth cations, and ammonium cations, and 
different aromatic compounds, such as naphthalene, heterocycles, and complete aromatic 
residues of Phe, Tyr, and Trp were used.10-16 Other influences such as counterions and 
water molecules on cation-π systems were also investigated both experimentally and 
computationally.12, 17-20 All these studies help us better understand the origin and wide 
application of cation-π interactions.  
  
Electrostatic potential surfaces are a very valuable tool in evaluating cation-π 
interactions.21 They provide a qualitative guide that faithfully tracks more quantitative 
efforts. Electrostatic potential surfaces were generated by mapping 6-31G** electrostatic 
potentials onto surfaces of molecular electron density. It is very interesting that AM1 
electrostatic potential surfaces represent very good approximations to the ab initio 
surfaces. Therefore, AM1 can provide a useful guideline for electrostatic potential 
surfaces.  
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14.4 18.9 32.6 27.5 23.2  
 
Figure 2.3 Ab initio electrostatic potential surfaces (EPS) of fluorinated Trp side chains. 
Blue region is positively charged while red region is negatively charged. The structure 
and number correspond to the EPS right above them. The numbers are the calculated 
sodium cation binding energy (kcal/mol) using HF/6-31G**.  
 
  
Fluorination of the indole ring of Trp withdraws the electron density from the 
aromatic system. As is illustrated from electrostatic potential surfaces, progressive 
fluorination of the Trp side chains makes charges in the ring centers less negative, 
diminishing cation-π interactions additively (Figure 2.3). The binding energies are 
calculated from the sodium and indole model system using HF/6-31G**. The progressive 
fluorination series can give convincing evidence for cation-π interactions in a ligand-
receptor recognition process.  
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2.1.2 The MOD-1 Receptor 
 
The MOD-1 receptor was discovered in 2000.22 It is a serotonin-gated chloride 
channel that modulates locomotory behavior in C. elegans. It belongs to the Cys-loop 
superfamily of ligand-gated ion channels (LGICs).  
The MOD-1 receptor is unique. It is activated by serotonin (5-hydroxytryptamine 
or 5-HT), similar to 5-HT3R.23 In contrast to 5-HT3R, it is not blocked by calcium ions or 
5-HT3-specific antagonists; instead, it is inhibited by the metabotropic 5-HT receptor 
antagonists, such as mianserin and methiothepin. MOD-1 conducts chloride anions, 
which is characteristic of inhibitory receptors such as the GABAA and glycine receptors. 
Besides chloride, MOD-1 channels are also permeable to other anions, such as 
thiocyanate and bromide. 
 Based on the structure of the nAChR, it is predicted that the MOD-1 receptor is a 
pentamer. To date, only one subunit has been reported. Each subunit has four 
transmembrane segments, M1–M4, with the M2 domain presumably lining the interior of 
the pore. A large extracellular N-terminus contains the ligand binding site (Figure 1.7). 
 
 
 
 
Figure 2.4 Sequence alignments for the key regions of the agonist binding sites. AChRG 
represents the γ subunit of nAChR; AChRA, α subunit. 
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In the region of the agonist binding site, MOD-1 and 5-HT3R are highly 
homologous. MOD-1 is 24% identical and 45% similar to 5-HT3R. Importantly, key 
aromatic residues of the agonist binding site are conserved in the two receptors (Figure 
2.4). 
 Most of what we know about the agonist binding site of the Cys-loop family of 
receptors came from studies of the nAChR.24 Extensive biochemical studies implicated a 
large number of aromatic residues as contributing to the binding site. These are 
associated with six so-called “loops” (loop A to loop F), which are different regions of 
sequence space that define the agonist binding site. Here we discuss only loops B, C, and 
D, as these are most conserved among the receptors considered (Figure 2.4). Studies of 
the nAChR using unnatural amino acid mutagenesis identified a key tryptophan, Trp 149 
in loop B, as making a potent cation-π interaction with acetylcholine in the binding site. 
The key to this study was the incorporation of a series of fluorinated Trp derivatives (Fn-
Trp, n = 1–4), showing that agonist potency tracked linearly with the cation-π binding 
abilities of the fluorinated rings (Table 2.2, Figure 2.7). These findings were subsequently 
supported by the crystal structure of AChBP (Figure 1.9), a soluble protein that is highly 
homologous to the agonist binding site of the nAChR. 
 Recently, the same approach was used to establish a similar binding motif for 
serotonin in the 5-HT3 receptor. In particular, Trp 183, the analogue of nAChR Trp 149, 
makes a strong cation-π interaction to the ammonium of serotonin, as evidenced by the 
fluorinated Trp study (Table 2.2, Figure 2.7). 
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As shown in Figure 2.4, MOD-1 also contains aromatic residues at the key 
locations, but with a subtle difference. The residue that aligns with Trp 183 of 5-HT3R is 
Tyr 180 of MOD-1. The key tryptophan that makes a cation-π interaction with serotonin 
(and acetylcholine) is now a Tyr. Of course, Tyr (and Phe) can also participate in cation-
π interactions,3 and so this conservative change (Trp to Tyr) is not startling.  
 
 
2.2 Electronic and Steric Effects on Ligand-Binding at Position 180 of MOD-1 
 
MOD-1 thus presents an opportunity to quantify a cation-π interaction between 
serotonin and a Tyr, allowing a direct comparison with the serotonin⋅⋅⋅Trp interaction in 
5-HT3R.  
 As a qualitative test of whether a cation-π interaction is important at position 180, 
we mutated Tyr to Phe and Trp. The EC50 of the Phe mutant (1.1 µM) is very close to that 
of wild type (1.2 µM) while EC50 of the Trp mutant (35.1 µM) is much greater (Table 
2.1). The calculated cation-π binding energies for Tyr, Phe, and Trp are 26.9, 27.1, 32.6 
kcal/mol, respectively (Figure 2.3 and Figure 2.5). The Tyr to Trp mutant increases the 
side chain size, partially occludes the agonist binding site, and leads to an increased EC50. 
Phenylalanine has a very similar effect as tyrosine at position 180 on both the EC50 
values and the cation-π binding ability, which indicates that the absence of a hydroxyl 
group does not produce a significant perturbation. Since the fluorination of tyrosine may 
perturb its pKa, we used phenylalanine at position 180 as the reference state to evaluate 
cation-π interactions in the following experiments.  
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Table 2.1 Mutations of Tyr 180 of MOD-1 
Residue EC50 (µM) nHill 
Tyr (Wild type) 1.2 ± 0.2 1.09 ± 0.18 
Phe 1.1 ± 0.1 1.08 ± 0.12 
4-F-Phe           213 ± 57 0.96 ± 0.12 
4-Cl-Phe           202 ± 52 0.81 ± 0.09 
4-Br-Phe           196 ± 46 0.88 ± 0.10 
3,4,5-F3-Phe           210 ± 69 0.71 ± 0.13 
4-Me-Phe          90.0 ± 8.6 0.90 ± 0.05 
4-MeO-Phe           316 ± 181 0.85 ± 0.13 
Trp          35.1 ± 7.0 0.90 ± 0.11 
5-F-Trp           127 ± 46 0.58 ± 0.07 
 
 
We used the in vivo nonsense suppression methodology for unnatural amino acid 
incorporation to substitute Tyr 180 of MOD-1 with several Phe analogues, including 
fluorinated residues of the sort that were so informative in studying the tryptophan 
interaction (Table 2.1). 
The EC50 values for 4-F-Phe, 4-Cl-Phe, and 4-Br-Phe at position 180 of MOD-1 
are 213 µM, 202 µM, and 196 µM, respectively, which are essentially the same. Since 
cation-π binding energies for 4-F-Phe (21.9 kcal/mol), 4-Cl-Phe (21.5 kcal/mol), and 4-
Br-Phe are close while steric effects are different, it seems that an electronic effect rather 
than a steric effect is important here.  
 The electrostatic potential surfaces (EPS) for the side chains of some 
phenylalanine derivatives used in the current studies are shown in Figure 2.5. F-Phe, Cl-
Phe, and Br-Phe, which have similar EPS, form much weaker cation-π interactions than 
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Phe, Tyr, 4-Me-Phe, and 4-MeO-Phe, which also have similar EPS among them. To 
further probe steric effects at Tyr 180, 4-Me-Phe and 4-MeO-Phe were incorporated into 
this position. 
 
 BrClF 
 
27.1 21.5  21.9 
 
 
26.9 
OH CH3 OCH3 F
F F
12.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 AM1 electrostatic potential surfaces of the side chains of phenylalanine 
derivatives. Blue region is positively charged while red region is negatively charged. The 
numbers beside molecular structures are the calculated sodium cation binding energy 
(kcal/mol) using HF/6-31G**.  
 
 
The EC50 values for 4-Me-Phe and 4-MeO-Phe are 90.0 µM and 316 µM, 
respectively. This result possibly means that a steric effect actually plays an important 
role at this site, too. However, Tyr and Phe have similar EC50 values; 4-F-Phe, 4-Cl-Phe, 
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and 4-Br-Phe also give similar behavior, which contradicts the importance of steric effect 
here.  
We found that these mutation studies yield puzzling and sometimes contradictory 
results. Possibly many factors play important roles at this site. The data showed no clear 
trend, and certainly not the remarkable trend seen when studying the Trp residues in 5-
HT3R or nAChR. 
 
 
 
2.3 Cation-π Interactions between Serotonin and Trp 226 of MOD-1 
Given these puzzling results, we considered a second subtle difference between 
MOD-1 and other Cys-loop receptors. Another canonical aromatic residue of the agonist 
binding site is Tyr 198 of the nAChR, aligning with Tyr 234 of 5-HT3R and Tyr 192 of 
AChBP. This Tyr is conserved in essentially all members of the family, but it is Trp 226 
in MOD-1. Given our earlier successes with studies of fluorinated Trp derivatives, we 
decided to apply the same protocol to Trp 226 of MOD-1.  
 
Table 2.2 Mutations of key aromatic residues (EC50, µM) 
 
Residue 149  
nAChRa 
183 
5-HT3b 
226 
MOD-1 
Cation-π 
Bindingc 
Trp 1.2±0.1 1.2±0.1 1.2±0.3 32.6 
5-F-Trp 4.7±0.1 6.0±0.5 12±1 27.5 
5,7-F2-Trp 13±0.1 37±3 66±11 23.3 
5,6,7-F3-Trp 34±0.1 240±8 240±50 18.9 
4,5,6,7-F4-Trp 65±0.3 – 1600±210 14.4 
a. Ref4.  The receptor has a Leu9’Ser mutation in M2.  b. Ref6.  c. kcal/mol   
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Figure 2.6 Electrophysiology recording of fluorinated tryptophans at position 226 of 
MOD-1. (a) Dose-response curves. (b) Representative voltage-clamp current traces for 
oocytes expressing suppressed MOD-1.  
 
 
The dose-response curves and representative electrophysiology traces are shown 
in Figure 2.6. The EC50 results are summarized in Table 2.2. We know that EC50 is a 
value reflecting both binding and gating of ion channels. However, since all the subtle 
mutations here are only made in the binding site and far away from the actual gating 
position, we assume that the mutations only affect binding, and that these EC50 values can 
represent the binding constants. Therefore, we can draw the plot of log [EC50/EC50(wt)] 
vs. cation-π interaction ability (Figure 2.7). Stunningly, the exact same trend seen for Trp 
183 of 5-HT3R is seen for Trp 226 of MOD-1. Both serotonin lines have steeper slopes 
than the analogous acetylcholine line, and the two serotonin lines have identical slopes. It 
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is thus estimated that cation-π interactions contribute to ligand binding in nAChR and 
serotonin receptors by ca. 2 kcal/mol and ca. 4 kcal/mol, respectively.6 Such agreement 
can only be interpreted to mean that the primary ammonium of serotonin makes a strong 
cation-π interaction with a Trp in both systems, but the two homologous receptors use a 
different tryptophan to make the cation-π interaction to serotonin.25 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
15 20 25 30 35
Cation-π Binding (kcal/mol)
lo
g[
E
C
50
/E
C
50
(w
t)]
 MOD-1   (226)
 
Trp
5-F-Trp
5,7-F2-Trp
5,6,7-F3-Trp
F4-Trp  5-HT3AR (183)
 nAChR (α149)
 
 
  
 
 
 
Figure 2.7 Fluorination effects versus cation-π binding energies. Red line represents 
cation-π site at Trp 226 in MOD-1; blue line, Trp 183 in 5-HT3R; black line, Trp 149 in 
nAChR. 
 
It thus appears that Nature has moved the critical cation-π binding interaction 
from the loop B site to the second loop C site on going from 5-HT3R to MOD-1. We 
emphasize that these are highly homologous receptors. On the basis of the AChBP 
structure, we estimate that the two critical residues are about 9 Å apart. Thus, while much 
of the serotonin molecule might occupy the same position in the two receptors, a 
significant rearrangement of the alkylammonium unit must occur on going from one 
receptor to the other. Note also that binding is not all that is happening. In both systems, 
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serotonin induces a large conformational change in the receptor, gating the ion channel. 
This makes it all the more remarkable that two binding orientations are possible.  
 
 
2.4 Switch of Tyr 180 and Trp 226 in MOD-1 
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Figure 2.8 Dose-response curves for the switch between Tyr 180 and Trp 226 of MOD-1. 
 
 
Superficially, it appears that Nature has simply swapped the Trp/Tyr pair of the 
agonist binding site. That is, we have Trp⋅⋅⋅Tyr in the nAChR (149⋅⋅⋅198) and the 5-HT3 
receptor (183⋅⋅⋅234), but Tyr⋅⋅⋅Trp in MOD-1 (180⋅⋅⋅226). To test this notion, we prepared 
the MOD-1 double mutant Y180W/W226Y by conventional mutagenesis. The results are 
shown in Figure 2.8. EC50 of the double mutant receptor (1200 µM) is 1000-fold higher 
than that of wild type (1.2 µM). Both single mutants Y180W (EC50, 35.1 µM) and 
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W226Y (EC50, 101 µM) are also substantially compromised. Similarly, the W183Y 5-
HT3R single mutant shows a 90-fold increase in EC50.26  
Thus, the MOD-1 and 5-HT3 receptors are precisely designed to bind serotonin, as 
would be expected. But the designs are different, and serotonin accommodates both. 
Another perspective on these data is that they provide testimony to the strength of the 
RNH3+⋅⋅⋅Trp cation-π interaction. Even when a perfectly acceptable Tyr is positioned in 
the “classical” cation-π site (the one used in nAChR and 5-HT3R), a Trp is preferable, 
and the ligand adjusts to reach it.  
 
 
2.5 Discussion 
 
The “lock and key” model for drug-receptor interactions has evolved over time. 
Certainly, proteins and small molecules are more flexible than their metaphorical 
counterparts, and some adaptation of one to the other is common. Nevertheless, the 
notion that proteins craft well-defined binding sites that are custom-tailored to their 
ligands remains central to analyses of biological recognition and drug discovery. 
The notion of a ligand held in a precise location by specific contacts to the protein 
has served enzymology, and drug discovery around enzymes, well. However, perhaps for 
receptors, molecules for which ligand binding induces a structural change that launches a 
signaling process, such a structured model is not necessary. Perhaps all that is required is 
for the ligand to occupy the binding region, acting more like a wedge, to initiate the 
conformational change. Standard forces of molecular recognition are required to direct 
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the ligand to the binding site, but the precise details of the binding interaction are less 
critical. In the present case, a cation-π interaction plays an important role in delivering 
serotonin to the binding site, but there is some flexibility as to the precise location of that 
interaction.  
Two highly homologous serotonin receptors, namely, MOD-1 and 5-HT3R, make 
use of different cation-π sites to bind the same agonist serotonin. While the full 
implications of these results for studies of drug-receptor interactions remain to be 
established, they immediately provide a caution for efforts to model binding sites based 
on sequence homology. It is entirely reasonable to assume that, since serotonin makes a 
cation-π interaction with Trp 183 in 5-HT3R, it would also make a cation-π interaction 
with Tyr 180 in MOD-1; any researcher would be comfortable with this modest 
substitution. However, our results show that instead of settling for the tyrosine, the 
agonist reorients in the binding site to contact a nearby tryptophan and thus maximize the 
cation-π interaction.  
 
 
2.6 Methods 
2.6.1 Electrophysiology 
 Electrophysiological recordings were made 24–72 hours after injection. Whole-
cell currents from stage VI oocytes of Xenopus laevis were measured in standard two-
electrode voltage clamp mode.27 Microelectrodes were filled with 3M KCl and the 
resistances were between 0.5 and 2 MΩ. Oocytes were continuously perfused with 
calcium-free ND96 bath solution. Serotonin was purchased from Sigma/Aldrich and all 
 46
drugs were prepared in calcium-free ND96 solution. Macroscopic serotonin-induced 
currents were recorded in response to bath application of the desired agonist 
concentration at a holding potential of -60 mV or -80 mV. Dose-response data were 
obtained from 3 to 5 oocytes and data were reported as mean ± standard error. Curves 
were fit to the Hill equation, I/Imax = 1/[1 + (EC50/[A])nH], where I is the current for 
agonist concentration [A], Imax is the maximum current, EC50 is the concentration to elicit 
a half-maximum response, and nH is the Hill coefficient.  
 
2.6.2 Incorporation of Unnatural Amino Acids by in vivo Nonsense Suppression 
Methods 
For suppression experiments, 25 ng of tRNA and 10 ng of mRNA were co-
injected in a total volume of 50 nL per oocyte. Immediately before the microinjection, the 
NVOC-aminoacyl-tRNA was deprotected by photolysis. The ligation of aminoacyl-dCA 
to tRNA and gene construction of suppressor tRNA have been described previously.28, 29 
The MOD-1 gene was subcloned into the plasmid pBlueScript. The MOD-1 TAG 
mutants were made by the QuickchangeTM site-directed mutagenesis method and were 
monitored by DNA sequencing. Plasmid DNAs were linearized with KpnI, and mRNA 
was transcribed using the Ambion T3 mMESSAGE mMACHINE kit.  
 For wild type and conventional mutation experiments, only 5 ng mRNA was 
injected into oocytes in a 50 nL volume per cell. The remaining procedure was the same 
as above. 
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2.6.3 Synthesis of Aminoacyl dCA (dCA-AA) 
 dCA-NVOC-4-fluorophenylalanine and dCA-NVOC-3,4,5-trifluorophenylalanine 
were synthesized according to previous procedures, as demonstrated in Scheme 2.1.30 
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Scheme 2.1 Synthetic scheme for aminoacylated dCA. 
 
 
NVOC-4-fluorophenylalanine (1a). 100 mg (0.55 mmol) of 4-fluorophenyl-
alanine and 87 mg (0.82 mmol, 1.5 eq) of sodium carbonate were dissolved in 12 ml of 
water and 10 ml of dioxane. A solution of 152 mg (0.55 mmol) of NVOC-Cl in 10 ml of 
dioxane was added dropwise. One hour later, the bright yellow reaction mixture was 
extracted with 3 × 25 ml of methylene chloride. The organic extracts were combined, 
dried over Na2SO4, filtered, and rotary-evaporated. The crude product was purified by 
flash chromatography using 1:1 ethyl acetate/petroleum ether to pure ethyl acetate to give 
a bright yellow solid (120 mg, 52%). 1H NMR (300 MHz, d6-acetone) δ 7.69 (s, 1H), 
7.35 (t, 2H), 7.13 (s, 1H), 7.05 (t, 2H), 6.90 (d, 1H), 5.42 (m, 2H), 4.49 (m, 1H), 3.93 (s, 
3H), 3,89 (s, 3H), 3,24 (m, 1H), 3.03 (m, 1H), 1.96 & 2.05 (m, 0.5H). 
  
NVOC-3,4,5-trifluorophenylalanine (1b). This compound was prepared by the 
procedure described above except using 3,4,5-fluorophenylalanine as the starting material. 
Yield: 60%. 1H NMR (300 MHz, d6-acetone) δ 7.69 (s, 1H), 7.20 (m, 2H), 6.98 (d, 1H), 
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5.42 (m, 2H), 4.49 (m, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.24 (m, 1H), 3.03 (m, 1H), 1.96 & 
2.05 (m, 1H). 
 
 NVOC-4-fluorophenylalanine cyanomethyl ester (2a). 60 mg (0.14 mmol) of 
NVOC-4-fluorophenylalanine (1a) was dissolved in 5 ml of anhydrous DMF. DIPEA (30 
µl, 0.17 mmol, 1.2 eq) and chloroacetonitrile (210 µl, 3.27 mmol, 23 eq) were added 
slowly. The reaction was stirred under argon at room temperature overnight. After 14 
hours, the reaction was quenched by adding 10 ml of 0.1 M KH2PO4 and 20 ml of water 
and then extracted with 3 × 40 ml of ethyl acetate. The combined organic layers were 
washed with 50 ml of water, dried over Na2SO4, and rotary-evaporated. Flash 
chromatography purification (1:3 to 1:2 to 2:1 ethyl acetate/petroleum ether) gave 40 mg 
(62%) of product. 1H NMR (300 MHz, CD2Cl2) δ 7.70 (s, 1H), 7.21 (m, 2H), 7.06 (m, 
2H), 6.99 (s, 1H), 5.48 (m, 4H), 4.73 & 4.80 (m, 3H), 3.92 (d, 6H), 3.18 (m, 2H), 2.93 (s, 
0.5H), 2.84 (s, 0.5H).  
  
NVOC-3,4,5-trifluorophenylalanine cyanomethyl ester (2b). Prepared as 
above except using 1b as the starting material.Yield: 90%. 1H NMR (300 MHz, CD2Cl2) 
δ 7.70 (s, 1H), 7.05 (s, 1H), 6.90 (t, 2H), 5.80 (d, 1H), 5.45 (m, 2H), 4.65 & 4.80 (m, 3H), 
3.92 (d, 6H), 3.18 (m, 2H), 2.93 (s, 2H), 2.84 (s, 2H). 
  
dCA-NVOC-4-fluorophenylalanine (3a). NVOC-4-fluorophenylalanine-
cyanomethyl ester (2a, 10 mg, 0.021 mmol) was mixed with the tetra-n-butyl-ammonium 
salt of the dCA dinucleotide (10 mg, 0.007 mmol) in 400 µl of anhydrous DMF. The 
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reaction was stirred under argon at room temperature.  After 1 hour TBA acetate (12 mg, 
0.04 mmol) was added to continue the reaction for another 2 hours. The crude product 
was separated using reverse-phase semi-preparative HPLC with a gradient from 25 mM 
ammonium acetate (pH 4.5) to CH3CN. The desired fractions containing the aminoacyl 
dinucleotide were combined, frozen, and lyophilized. Ammonium ions were removed by 
redissolving the product in 10 mM aqueous acetic acid/acetonitrile, followed by 
lyophilization. The product (3.9 mg, 20%) was quantified by UV/Vis spectra and 
characterized by mass spectrometry. ESI-MS: found [M-H]-: 1039.4, calculated for 
C38H43N10O20P2F 1040.4. 
  
dCA-NVOC-3,4,5-trifluorophenylalanine (3b). Prepared as above except using 
2b as the starting material. Yield: 23%. ESI-MS: found [M-H]-: 1075.4, calculated for 
C38H41N10O20P2F3 1076.4. 
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Chapter 3 
 
Prediction of the Ligand-Binding Site of MOD-1: Implications 
for the Hydrogen Bonding Pattern of Serotonin 
 53
3.1 Introduction 
 
In Chapter 2, using the unnatural amino acid mutagenesis methodology, we 
showed that the primary ammonium group of serotonin forms a cation-π interaction with 
Trp 226 of MOD-1 (Figure 2.6).1 Here, we continue our efforts to obtain more details on 
the ligand-binding site.   
 
 
1
5
Indolic amine group
Terminal ammonium
Hydroxyl group
 
 
 
 
 
 
 
Figure 3.1 Potential hydrogen bonding positions of serotonin in the MOD-1 receptor. As 
indicated by the arrows, the terminal ammonium, indolic amine group, hydroxyl group 
can potentially form hydrogen bonds with the receptors. 
 
 
Upon binding, the agonist serotonin can potentially form hydrogen bonds with the 
MOD-1 receptor at three positions. As shown in Figure 3.1, the terminal primary 
ammonium cation and the indolic amine group can act as hydrogen bond donors; the 
hydroxyl group can act as both a hydrogen donor and an acceptor. If we can identify the 
hydrogen bonding pattern of serotonin inside the binding pocket, the entire orientation of 
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the ligand will be fixed at the chemical level, and non-covalent interactions responsible 
for binding will be elucidated. Ultimately, we will obtain high-resolution information on 
the binding pocket with the ligand bound.  
However, this task is challenging. We do not have crystal structures of MOD-1. 
Most of our knowledge on the ligand-binding site of the Cys-loop superfamily comes 
from nAChR.2 The ligand binding site lies in the large N-terminal extracellular domain 
between two subunits of the receptor. Photoaffinity labeling, radioligand binding, and 
mutational studies have been used to establish that several loops (loop A to loop F), 
which are different regions of sequence, define the ligand-binding sites (Figure 1.8). 
Currently, for MOD-1, we only know that a cation-π interaction exists between the 
primary ammonium of serotonin and Trp 226 of MOD-1. Sequence alignments of MOD-
1 with nAChR indicate that residues from loop A to loop F in MOD-1 are important in 
binding the ligand. Both the main chains and side chains of many residues are the 
hydrogen bond candidates; in addition, there are three possible hydrogen bonding 
positions in serotonin. The hydrogen bond pattern of serotonin inside the binding pocket 
can have a large amount of variations. Therefore, it is difficult to establish this hydrogen 
bonding pattern without further guidance.  
Fortunately, our anxiety over this challenging task is relieved by the 
determination of the crystal structure of the acetylcholine binding protein (AChBP) and 
the development of computational modeling methods.  
Recently, Sixma and co-workers reported the crystal structure of acetylcholine 
binding protein (AChBP), which is homologous to the extracellular domain of the Cys-
loop superfamily.3 AChBP shares about 20% sequence identity with the Cys-loop 
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superfamily and has the key loops (loop A to loop F), which are important in binding the 
ligand. AChBP is an excellent template to perform the homology modeling study on the 
Cys-loop superfamily.  
Therefore, we can obtain a homology model of a receptor using AChBP as the 
template. In order to obtain the orientation of the ligand, we need to further dock the 
ligand into the binding site of the receptor. Some homology modeling tools such as 
MODELLER, and docking programs such as DOCK have been developed, and their 
applications in structure-based ligand and drug design have been reviewed.4  
Many modeling studies on the Cys-loop superfamily have appeared since the 
arrival of the AChBP crystal structure. The structures of nAChR with agonists such as 
acetylcholine, nicotine, or epibatidine, in the binding site were modeled.5, 6 Using 
molecular dynamics simulations, the Sine group showed that the curariform antagonists 
adopted different orientations in both AChBP and nAChR, which was further confirmed 
by corresponding experiments.7-9 More recently, the Sine group revealed that upon 
agonist binding in AChBP, loop C moved inward to occlude the entrance of the binding 
site.10 The ligand orientations in the binding pockets have also been predicted in the 
GABAA and 5-HT3 receptors.11-13 
In this chapter, HierDock was used to dock serotonin and several other agonists 
into the extracellular domain of MOD-1, which was built from the AChBP template. The 
cation-π interaction between the primary ammonium cation of serotonin and Trp 226 was 
demonstrated. Most impressively, a hydrogen bonding pattern of serotonin in the binding 
pocket was suggested. Side chains of Asn 223 and Gln 228, and the main chain carbonyl 
group of Tyr 180 form hydrogen bonds with the hydroxyl group, indolic amine group, 
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and the terminal ammonium of serotonin, respectively. This detailed binding pattern will 
give us directions for further experiments.   
 
 
3.2 Methods 
3.2.1 Sequence Alignment 
 The extracellular domains of MOD-1 and 5-HT3R were aligned with AChBP (pdb 
id: 1I9B) using the program CLUSTALW.14 Some manual adjustments were made 
according to the knowledge of the binding sites. 
 
3.2.2 3-D Model Building 
 The program MODELLER (Version 6) was used to perform homology modeling 
of MOD-1 using AChBP as the template.15 Each subunit was built separately. The 
coordinates of the five subunits were then assembled to generate the whole 
homopentamer of MOD-1. 
Hydrogens were added using Biograf. Protein was described by CHARMM22 
charges,16 and counterions (Na+ and Cl-) were added to balance charged residues. The 
solvation effect was simulated by the surface-generalized Born (SGB) implicit solvation 
model.17 The whole protein was then minimized using MPSim18 with the Dreiding force 
field.19 Since the sequence identity between MOD-1 and AChBP is about 16% and the 
sequence similarity is about 60%, the quality of the minimized MOD-1 protein was 
evaluated by the Protein Health Utility implemented in QUANTA.  
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3.2.3 Agonist Docking by HierDock 
 HierDock is a recently developed docking algorithm.20-22 It has been successfully 
applied to predict the binding sites of GPCRs and aminoacyl-tRNA synthetases.21, 23 The 
HierDock protocol is based on DOCK 4.0.24  
The charges of all the agonists were taken from quantum chemical calculations at 
the B3LYP/6-31G** level after full optimization using Jaguar 4.0. Although the protein 
is a homopentamer, only one agonist was chosen to be docked into one of the ligand-
binding sites. 
First, we needed to define the binding pocket for the agonist. We know that the 
ligand-binding site lies between two subunit interfaces. Previous study on MOD-1 shows 
that a cation-π interaction exists between the terminal primary ammonium of serotonin 
and Trp 226. Therefore, serotonin was manually docked to the subunit interfaces with the 
primary amine N atom in serotonin sandwiched between Tyr 180 and Trp 226 of one 
subunit. In order to probe the agonist conformation space more thoroughly inside the 
binding site, we generated twelve starting orientations of the agonist. The hydroxyl group 
and indole N atom in serotonin were rotated inside the binding pocket to obtain twelve 
different initial orientations, which sampled the steric-permitted spaces nearby.  
For each initial orientation, the corresponding binding site was defined as the 
cube occupied by the ligand plus a 5 Å margin in each dimension. An energy grid was 
then generated for the binding region plus a 10 Å margin for each dimension. Therefore, 
altogether twelve binding regions were defined for further docking.  
For each binding region, the Monte Carlo method was used to generate 5000 
ligand conformations to match the void regions. The ligand conformation was minimized 
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and binding energy was calculated. According to the energy scoring function, the top 50 
conformations were chosen for further evaluation. MPSim was used to minimize the top 
50 conformations in the presence of the receptor. The top five conformations were chosen 
to run another cycle of minimization including the AVGB solvation model. The one with 
the lowest energy was chosen as the docking result.  
The binding energy (BE) was defined as the following: 
BE = Energy (complex) – Energy (free protein) – Energy (free ligand) 
where the energy included the solvation effect.  
Therefore, for twelve initial binding regions, we obtained twelve docking results 
of serotonin. Comparison of the binding energies as well as the overall orientations of 
serotonin inside the binding pocket gave us the preferred docking conformation of 
serotonin for further refinement.  
For other agonists, only one initial docking region was used according to that of 
serotonin, which yielded the final preferred docking conformation. Then the above 
HierDock procedure was used to obtain the preferred docking conformation for the 
corresponding agonists. The binding energies from the preferred docking conformations 
were used to compare with the binding affinities of the agonists.  
 
3.2.4 Side Chain Optimization by SCREAM 
Using the preferred binding conformation of serotonin, the side chains for all the 
residues within 5 Å of the bound serotonin were optimized using the SCREAM side chain 
optimization program. The rotamer library of amino acids was used to mutate the side 
chains of those residues. After brief minimizations, the new structure with lowest energy 
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was taken for further analysis. This step would give more flexibility to the binding 
pockets thus optimizing the intermolecular interactions, e.g., the hydrogen bonds. 
 
3.2.5 Serotonin Re-docking by HierDock 
The new structure obtained from SCREAM was applied to the HierDock 
procedure again for relaxation.  
After this re-docking step, we obtained our final docking orientation of serotonin 
inside this binding site.  
 
3.3 Results 
AChBP FDRADILYNIRQTSRPDVIPTQRD-R-PVAVSVSLKFINILEVNEITNEVDVVF-WQQTTWSDRTLAWNSSHSP- 
MOD-1 WSEGKI-MNTIMSNYTKMLPDAED-S--VQVNIEIHVQDMGSLNEISSDFEIDILFTQL-WHDSALSFAHLPAC- 
5-HT3 PALLRLSDHLLANYKKGVRP-VRDWRKPTTVSIDVIMYAILNVDEKNQVLTTYI-WYRQYWTDEFLQWTPEDFDN 
               Loop D 
 
AChBP -DQ----VSVPISSLWVPDLAAYNAISKPEVLTP---QLARVVSDGEVLYMPSIRQRFSCDVSGVDTESG-AT-C 
MOD-1 -KRNITMETRLLPKIWSPNTCMINSKRTTVHASPSENVMVILYENGTVWINHRLSVKSPCNLDLRQFPFDTQT-C 
5-HT3 VTK----LSIPTDSIWVPDILINEFVDVGKSPNI---PYVYVHHRGEVQNYKPLQLVTACSLDIYNFPFD-VQNC 
 
 
         Loop A   Loop E  
AChBP RIKIGSWTHHSREISVDPT---TENSDDSEYFSQYSRFEILDVTQKKNSVTYSCCP-EAYEDVEVSLNFRKKG 
MOD-1 ILIFESYSHNSEEVELH-W---MEEAVTLMKPIQLPDFDMVHYSTKKETLLYPNG---YWDQLQVTFTFKRRY 
5-HT3 SLTFTSWLHTIQDINITLWRSPEEVRSDKSIFINQGEWELLEVFPQFKE--FSIDISNSYAEMKFYVIIRRRP 
     Loop B    Loop F             Loop C 
 
Figure 3.2 Sequence alignment of the amino-terminal domain of MOD-1 (C. elegans), 5-
HT3AR (mouse), and AChBP (snail). The characteristic Cys-loop was colored yellow; the 
key loops responsible for ligand-binding were also noted; the key aromatic residues were 
colored red.       
 
 
3.3.1 Model of MOD-1 
 The sequence alignment of the amino-terminal domain of MOD-1, 5-HT3AR, and 
AChBP is shown in Figure 3.2. The key binding loops (loop A to loop F) are labeled. The 
model of MOD-1 after minimization is shown in Figure 3.3.  
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igure 3.3 Model of MOD-1 after minimization. Subunit A is colored blue and subunit B 
olet. (a) Top view of the homopentamer from the synaptic cleft. (b) Side view. Loop A 
 loop F are colored red. Figures were generated using Pymol (a) and Rasmol (b). 
The secondary structures of AChBP are well-conserved in the model of MOD-1: 
ach subunit starts with a α-helix and continues with the core β strands. The Cys-loop is 
sitioned between β6 and β7 strands. The binding site of serotonin lies between the 
bunits interface. As in Figure 3.3, the residues in loops A, B, C from subunit A consist 
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of the primary binding pocket of serotonin, while the residues in loops D, E, F from 
subunit B define the complementary part.  
 
3.3.2 The Binding Pocket of Serotonin in MOD-1 
 
Table 3.1 Docking results of serotonin in MOD-1 from the twelve initial binding 
orientations (DB stands for defined binding orientation).  
 
 Binding energy 
(kcal/mol) 
Hydrogen bond partner of the 
hydroxyl group in serotonin 
 DB1  -155.85 Asn223 
DB2 -152.66 – 
DB3 -161.76 – 
DB4 -170.54 Asn223 
DB5 -162.14 – 
DB6 -162.32 – 
DB7 -158.88 – 
DB8 -152.00 – 
DB9 -162.10 – 
DB10 -159.52 – 
DB11 -154.79 – 
DB12 -164.16 – 
 
 
The docking results from the twelve initial orientations of serotonin in MOD-1 are 
summarized in Table 3.1. For all the above twelve docking results, there is no hydrogen 
bond between the receptor and the indole N atom of serotonin. In two cases, namely, the 
results from DB1 and DB4, a hydrogen bond forms between the hydroxyl group of 
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serotonin and Asn 223 of MOD-1. Especially, the docking result from DB4 has the 
lowest energy among all the twelve and shows that the primary amine N atom of 
serotonin lies right above the center of the six-membered ring of Trp 226. Therefore, we 
used the preferred docking result from DB4 for further refinement. 
 
After side chain optimization by SCREAM and re-docking, we obtained the final 
docking conformation of serotonin in the binding pocket (Figure 3.4). Serotonin is 
represented using a space-filling model, lying between two subunit interfaces (Figure 3.4 
(a)). All the MOD-1 residues within 5 Å of serotonin are summarized in Table 3.2. 
Impressively, the binding pocket of serotonin including the hydrogen bonding pattern is 
very informative after this refinement step.  
 
 
Table 3.2 MOD-1 residues around 5 Å of serotonin.  
Residues Loops 
F83 Loop D (–)b 
I122 Loop A (+)a 
I140 Loop E (–) 
I176, E178, S179, Y180, S181, H182 Loop B (+) 
L219, Y221, N223, W226, D227, Q228 Loop C (+) 
 
a “+” means the primary binding pocket on subunit A. b (-) means the complementary 
binding pocket on subunit B. 
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Figure 3.4 Docking result of serotonin in MOD-1. (a) Overall side view. (b) Cation-π 
interaction pattern. (c) Hydrogen bonding pattern. Figures were generated using Pymol. 
W226 Y180
(b) 
Q228
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From Table 3.2, we can see that at least one residue from loop A to loop E 
contributes to the binding site. This docking orientation also confirms that loops A, B, 
and C define the primary binding pocket and that loop D and E form the complementary 
part. It seems that loop B and loop C are the most important in binding the ligand since 
more residues from these two loops are around serotonin.  
Ile 122 in loop A, the homolog of Tyr 93 in nAChR (Figure 1.8), is above the 
five-membered ring of serotonin. The shortest distance between Ile 122 and serotonin is 
only 2.80 Å. Phe 83 in loop D, the homolog of Trp 55 in nAChR (Figure 1.8), is above 
the six-membered ring of serotonin. The nearest distance between Phe 83 and serotonin is 
4.03 Å. The benzene ring of Phe 83 can have a T-shape aromatic interaction with the six-
membered ring of serotonin.  
The cation-π interaction pattern of serotonin is shown in Figure 3.4 (b). The 
primary amine of serotonin is sandwiched between the aromatic rings of Trp 226 in loop 
C and Try 180 in loop B. The distance between the primary amine N atom of serotonin 
and the center of the six-membered ring of Trp 226 is 3.5 Å, while the distance between 
the N atom and the center of the six-membered ring of Tyr 180 is 3.8 Å. However, the 
primary amine of serotonin lies only well above the center of the six-membered ring of 
Trp 226. Therefore, the cation-π interaction of Trp 226 is much stronger than that of Tyr 
180. This cation-π interaction acts as an important driving force to direct the primary 
amine of serotonin into the corresponding position inside the binding pocket.  
The hydrogen bonding pattern of serotonin is shown in Figure 3.4 (c). First, the 
side chain amide carbonyl group of Gln 228 forms a hydrogen bond with the indolic 
amine group of serotonin. The heavy atom distance is 2.9 Å. Second, the side chain 
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amide group of Asn 223 hydrogen bonds with the hydroxyl group of serotonin. In our 
model, one N-H in the amide group of Asn 223 is the hydrogen bond donor and the 
oxygen atom in the hydroxyl group of serotonin is the acceptor. The heavy atom distance 
is 2.9 Å. Third, the main chain carbonyl group of Tyr 180 forms a hydrogen bond with 
the primary ammonium cation of serotonin. The distance between the carbonyl oxygen 
atom and the amine nitrogen atom is 2.9 Å. 
 
 The hydrogen bonding pattern and aromatic interactions between the agonist 
serotonin and the receptor are well-illustrated by the docking result. This high-resolution 
image of the binding pocket provides us an excellent direction for our future experiments.  
 
 
3.3.3 Docking of Other Agonists 
  
Some other agonists were also docked into MOD-1 using the DB4 binding region. 
The structures of the agonists are shown in Figure 3.5. N-methyl-serotonin and α-methyl-
serotonin are serotonin derivatives, methylated at different sites, which will provide some 
steric perturbation around the primary amine of serotonin. Tryptamine will explore the 
importance of the hydroxyl group in serotonin. Although these agonists adopt slightly 
different orientations inside the binding pocket compared to serotonin, the overall binding 
pockets remain very similar.  
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        (a)      (b)         (c)             (d) 
Figure 3.5 The structures of agonists docked into MOD-1. (a) Serotonin. (b)  α-methyl-
serotonin. (c) Tryptamine. (d) N-methyl-serotonin.  
 
 
 The binding energies of the agonists are summarized in Table 3.3. The EC50 
values of the agonists from the experiments are also shown. Each agonist will open the 
channel and elicit some current. EC50 is the concentration at which the agonist will 
induce half the maximal current. EC50 represents the potency of one agonist.  
 
 
Table 3.3 Binding Energy and EC50 of different agonists of MOD-1.  
 Binding Energy (kcal/mol) EC50 (µM) 
Serotonin -170.54 1.2 ± 0.3 
α-methyl-serotonin -163.34 2.8 ± 0.6 
tryptamine -158.13 26 ± 3 
N-methyl-serotonin -152.80 37 ± 4 
 
  
The smaller the binding energy, the more potent the agonist (Table 3.3). From the 
binding energies of different agonists we can postulate their relative potency. Thus we 
can have the order of potency: serotonin > α-methyl-serotonin > tryptamine > N-methyl-
serotonin. The more potent the agonist, the smaller the EC50 value. Therefore, a smaller 
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binding energy corresponds to a smaller EC50 value for an agonist. This is the case when 
we compare the computed binding energy to the experimentally measured EC50 values of 
these agonists. 
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Figure 3.6 Linear correlation between binding energy and logEC50 of different agonists 
of MOD-1. 
 
  
The logEC50 value is related to the energy scale. We can plot 
log(EC50(agonist)/EC50(serotonin)) versus the binding energy calculated from the 
docking. As in Figure 3.6, this yields a nice linear correlation. Therefore, it is possible to 
use the calculated binding energy to postulate the potency of an unknown agonist, which 
will benefit structure-based drug design.  
It needs to be pointed out that during the binding energy calculation the empirical 
force field was applied to the whole complicated ligand-protein complex, which possibly 
 68
will not fully reflect the behavior of the ligand-binding pocket. If we can describe the 
ligand-binding pocket with the quantum mechanics (QM) method and other protein 
portions with the molecular mechanics (MM) method, more accurate binding energies 
will be obtained, and thus, the relative potency of agonists can be predicted with more 
confidence. This hybrid method is called QM/MM method and has been applied in other 
biological systems.25 The implementation of the QM/MM method into the complicated 
ligand-receptor recognition system will help us better understand this process. 
 
 
3.4 Conclusions and Discussion 
  
Serotonin was docked into the ligand-binding pocket of MOD-1 built from the 
AChBP template. The main purpose of this docking study was to find the hydrogen 
bonding pattern of serotonin in MOD-1. Most impressively, after the refinement step, a 
vivid hydrogen bonding pattern was obtained (Figure 3.4).  
 
From the model, the main chain carbonyl group of Tyr 180 can hydrogen bond 
with the primary amine of serotonin. The incorporation of an α-hydroxy acid at Ser 181 
will introduce the amide-to-ester backbone mutation. The hydrogen bond acceptor ability 
of the main chain carbonyl group of Tyr 180 will then decrease. This subtle change can 
be used to prove that hydrogen bond.  Hydrogen bonds exist between Asn 223 / Gln 228 
and serotonin in the model. We can perturb the receptor as well as the agonist with proper 
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designs. This forward and reverse pharmacology strategy will be applied to confirm the 
corresponding hydrogen bonds.   
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Figure 3.7 Combination of computation and experiment to study the ligand-binding site 
of the MOD-1 receptor. 
 
 
To study the ligand-binding site of MOD-1, we performed some experiments as 
described in Chapter 2. We mutated the structure using the powerful unnatural amino 
acid mutagenesis method, monitored the function by electrophysiological recording, and 
gained some knowledge about the binding site. In order to obtain more detailed 
information on the binding pocket, in this chapter, based on our current knowledge from 
experiment, we continued to build a homology model of MOD-1, and docked the agonist 
into this homology model. We gained a detailed image of the agonist in the binding site. 
The next step is to prove this model by experiments, which will be discussed in Chapter 4. 
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Therefore, when used in conjunction with one another, experimental chemistry and 
computational chemistry complement one another (Figure 3.7).  
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Chapter 4 
 
Hydrogen Bonding Pattern of Serotonin in MOD-1 
 74
4.1 Introduction 
 
The modeling study in Chapter 3 showed that serotonin could form three 
hydrogen bonds in the binding pocket of MOD-1 (Figure 3.4). First, the side chain amide 
carbonyl group of Gln 228 forms a hydrogen bond with the indolic amine group of 
serotonin (Figure 4.1 (a)). Second, the side chain amide group of Asn 223 hydrogen 
bonds with the hydroxyl group of serotonin (Figure 4.1 (b)). Third, the main chain 
carbonyl group of Tyr 180 forms a hydrogen bond with the primary ammonium cation of 
serotonin (Figure 4.1 (c)). Therefore, we had a high-resolution model of the binding 
pocket with serotonin bound.  
 
 
 
 
 
 
Q228
5-HT
2.9 Å
N223
5-HT
2.9 Å
5-HT
S181
Y180
2.9 Å
(c)(b)(a) 
Figure 4.1 Hydrogen bonding pattern of serotonin in MOD-1. (a) H-bond between Q228 
and 5-HT. (b) H-bond between N223 and 5-HT. (c) H-bond between the main chain 
carbonyl group of Y180 and 5-HT. 
 
 
In this chapter, we aim to prove this hydrogen bonding pattern experimentally. In 
order to confirm the hydrogen bond between a ligand and a specific residue in a receptor, 
we need to show: first, the specific residue forms a hydrogen bond; second, the ligand is 
the actual hydrogen bond partner of this specific residue. To prove the first point that a 
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specific residue forms a hydrogen bond, we can change the structure of this residue to 
perturb its hydrogen bonding ability and monitor the resulting functional change. 
Conventional mutations can be used as a starting point for this purpose. Furthermore, 
with the powerful unnatural amino acid mutagenesis methodology,1 we can finely tune 
the hydrogen bonding ability of this residue and thus confirm this point with more 
confidence. To prove the second point that the ligand is the actual hydrogen bond partner 
of this specific residue, we need to modify the hydrogen bonding ability of the ligand. 
Such a study can then be performed on structures where both the ligand and the residue 
change, which will give compelling evidence on the hydrogen bond between the ligand 
and the specific residue. If forward pharmacology is used to describe the structural 
modification of the ligand, and reverse pharmacology to the residue, this strategy can 
then be termed as the forward and reverse pharmacology method.  
 
The forward and reverse pharmacology method was applied to test the hydrogen 
bonding pattern of serotonin in MOD-1. The hydrogen bond between the indolic amine 
group of serotonin and Gln 228 was confirmed. Furthermore, the EC50 values measured 
in the experiments were in good agreement with the hydrogen bond binding energies 
calculated from the ab initio quantum chemical method. Our current results showed that 
it is possible that the two hydrogen bonds between serotonin and Asn 223 and the main 
chain carbonyl group of Tyr 180 exist. Therefore, we obtained a high-resolution image of 
the orientation of serotonin in the binding pocket, which could benefit the study of the 
Cys-loop superfamily of ligand-gated ion channels and drug design efforts. 
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4.2 Hydrogen Bond between Gln 228 and the Indolic Amine Group of Serotonin 
4.2.1 Use of Serotonin Analogues and Conventional Mutations to Probe the 
Hydrogen Bond between Gln 228 and Serotonin 
 
 
 
N
H
HO
NH3
N
H
NH3
O
NH3 
 
 
 
 
Figure 4.2 Structures of serotonin analogues used to probe the hydrogen bond between 
serotonin and Gln 228. The molecule in green is serotonin; the molecule in magenta is 
tryptamine; the molecule in dark yellow is 2-(benzofuran-3-yl)ethylamine (BFEA).  
 
 
 
Several serotonin analogues were used to probe the hydrogen bond between 
serotonin and Gln 228. As shown in Figure 4.2, serotonin is colored green, tryptamine 
colored magenta, and 2-(benzofuran-3-yl)ethylamine (BFEA) colored dark yellow. 
Compared to serotonin, tryptamine only lacks a hydroxyl group, deleting the potential 
hydrogen bond formation ability at this position. Compared to tryptamine, BFEA 
substitutes the indole nitrogen with an oxygen atom, removing the hydrogen bond donor 
ability at this position. Tryptamine and BFEA modify the hydrogen bonding ability of 
serotonin at different positions. The use of these three drugs simultaneously will give 
valuable information on the hydrogen bond partners of serotonin in the binding pocket. 
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Figure 4.3 Dose-response curves of serotonin analogues in the MOD-1 wild type and 
L9’T and L9’S mutants. (a) Serotonin analogues recorded in wild type. (b) Serotonin 
curves recorded in wild type and L9’T and L9’S mutants. (c) Tryptamine curves recorded 
in wild type and L9’T and L9’S mutants. (d) BFEA curves recorded in wild type and 
L9’T and L9’S mutants. 
 
 
We measured dose-response curves of these drugs in the MOD-1 wild type. The 
results are summarized in Figure 4.3 (a) and Table 4.1. Tryptamine had a higher EC50 
value (26 µM) than serotonin (1.22 µM), and BFEA had an even higher EC50 value (118 
µM) although much lower efficacy than serotonin and tryptamine. This EC50 trend agreed 
with the docking result that both the hydroxyl group and the indolic amine of serotonin 
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formed hydrogen bonds with the receptor because deletion of the hydrogen bonding 
ability at either of these two positions impaired the drug potency.  
 
Table 4.1 EC50 values of serotonin analogues in MOD-1 wild type and L9’T and L9’S 
mutants.   
 5-HT 
 
Tryptamine BFEA 
EC50 (µM) 
 
1.22±0.30 26±3 118±7  
WT 
nHill 
 
1.17±0.06 1.39±0.22 1.17±0.06 
EC50 (µM) 
 
0.042±0.005 1.92±0.09 14.5±2.0  
L9’T 
nHill 
 
1.36±0.12 1.36±0.07 1.62±0.22 
EC50 (µM) 
 
0.033±0.003 1.20±0.11 8.51±1.64  
L9’S 
nHill 
 
0.87±0.10 1.31±0.12 1.31±0.28 
 
 
Next, we did a simple test to see whether these three drugs had similar gating 
mechanisms. From the study of nAChR, it is known that Leu 9’ in the M2 region is the 
actual gate of the ion pore.2 In nAChR, L9’T and L9’S mutations can shift the dose-
response relationship to lower concentrations.3, 4 Thus, using these three drugs, we 
recorded the dose-response curves of the L9’T and L9’S mutants in MOD-1. The results 
are shown in Figure 4.3 and Table 4.1. Both the L9’T and L9’S mutations shifted the 
EC50 curves to the left for all these three drugs with similar trends. Therefore, these three 
drugs did not differ significantly in their gating pathways, thus, providing good 
comparisons with each other in studying the binding behavior of MOD-1. 
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Figure 4.4 Structures of conventional mutations made at position 228 of MOD-1. 
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Figure 4.5 Dose-response curves of serotonin analogues in Q228N, Q228E, Q228A 
mutants of MOD-1. (a) Serotonin was used for recording. (b) Tryptamine was used for 
recording. (c) BFEA was used for recording. 
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With the three serotonin analogues at hand, we mutated Gln 228 to glutamate, 
asparagine, and alanine to modify its hydrogen bonding ability (Figure 4.4). The dose-
response curves of these mutants using the three serotonin analogues were measured. The 
results are summarized in Figure 4.5 and Table 4.2. 
 
 
Table 4.2 EC50 values of serotonin analogues in Q228N, Q228E and Q228A mutants of 
MOD-1.  
Position 228 5-HT 
 
Tryptamine BFEA 
EC50 (µM) 
 
1.19±0.20 28±1 121±12 
 
 
Q228N 
nHill 
 
1.18±0.20 1.23±0.05 1.21±0.06 
EC50 (µM) 
 
0.49±0.05 8.50±0.63  
Q228E 
nHill 
 
1.00±0.10 1.50±0.13 
 
NRa 
EC50 (µM) 
 
5.75±0.50 170±20 133±10  
Q228A 
nHill 
 
1.02±0.11 0.91±0.10 1.11±0.10 
a NR represents no response.  
 
When serotonin was used for recording, Asn gave a similar EC50 value (1.19 µM) 
to the wild type Gln (1.22 µM), which is indicated by the red dose-response curve 
(Q228N) in Figure 4.5 (a). Asn has the terminal amide group and is only one carbon 
shorter than Gln. The Gln to Asn mutation could still keep the hydrogen bond between 
serotonin and the amide carbonyl group of the residue at position 228, and thus, did not 
change the EC50 value. The Glu mutant (EC50, 0.49 µM) shifted the dose-response curve 
to the left, which is indicated by the black curve (Q228E) in Figure 4.5 (a). This was in 
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accordance with the prediction that the Gln to Glu mutation increased the electron density 
of the oxygen atom forming the hydrogen bond, thus potentiating the hydrogen bonding 
ability. The Ala mutant (EC50, 5.75 µM) shifted the dose-response curve to the right, 
which is indicated by the blue curve (Q228A) in Figure 4.5 (a). This result agreed with 
the expectation that the Gln to Ala mutation deleted the hydrogen bond, thus impairing 
the agonist potency. The current study on these mutations showed that Gln 228 
participated in hydrogen bond formation, which would be further proved by unnatural 
amino acid mutations. However, we still needed to confirm that the actual hydrogen bond 
partner of Gln 228 was the indolic amine of serotonin.  
When tryptamine was used for recording, the dose-response curves for the three 
mutations had the same trend as those using serotonin (Figure 4.5 (b)). The Asn mutant 
had a similar EC50 to wild type; the Glu mutant, decreased EC50; the Ala mutant, 
increased EC50.  Serotonin and tryptamine had similar responses to the mutations at Gln 
228. This result showed that the hydrogen bond partner of Gln 228 was not the hydroxyl 
group of serotonin. Therefore, the model of the indolic amine of serotonin acting as the 
hydrogen bond donor was supported.  
Finally, we used BFEA to perform the recordings. BFEA had a distinctively 
different response profile to these mutations at Gln 228 from serotonin and tryptamine 
(Figure 4.5 (c)). Using BFEA, both the Asn and Ala mutants produced similar EC50 
values to wild type. The current of the Glu mutant was too small to calculate the EC50 
value. The mutations at Gln 228 did not affect the binding of BFEA, which confirmed 
that the actual hydrogen bond partner of Gln 228 was the indolic amine of serotonin!  
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As described above, to probe the hydrogen bond between Gln 228 and serotonin, 
we modified the hydrogen bonding abilities of both Gln 228 using conventional 
mutagenesis and serotonin at the specific sites using proper drugs. This purposely 
designed structure-function study strongly supported the model that a hydrogen bond 
exists between the side chain amide carbonyl group of Gln 228 and the indolic amine of 
serotonin (Figure 4.1 (a)).  
 
4.2.2 Use of Unnatural Amino Acid Mutations to Further Prove the Hydrogen 
Bond between Gln 228 and Serotonin 
4.2.2.1 Model Study of the Hydrogen Bond Binding Energies between Gln 228 and 
Serotonin 
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Figure 4.6 AM1 electrostatic potential surfaces (EPS) of the model molecules that 
represent the Gln analogues. Red region is negatively charged; blue region is positively 
charged. The structures shown correspond to the EPS right above them.  
 
 
Using the powerful unnatural amino acid mutations, we can subtly tune the 
hydrogen bonding ability of Gln 228. In order to modify the hydrogen bond acceptor 
ability of the side chain amide carbonyl group in Gln 228, we can substitute the terminal 
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amine with a methyl group first. This substitution deletes the potential hydrogen bond 
formation ability of the terminal amine. Then the terminal methyl ketone can be 
progressively fluorinated, which decreases the hydrogen bond acceptor ability of the 
carbonyl group little by little. This trend is vividly shown by the electrostatic potential 
surfaces of some simple model molecules by the AM1 semi-empirical method (Figure 
4.6).  
As shown in Figure 4.6, acetamide represented glutamine, acetone represented 2-
amino-5-oxohexanoic acid, fluoroacetone represented 2-amino-6-fluoro-5-oxohexanoic 
acid, 1,1-difluoroacetone represented 2-amino-6,6-difluoro-5-oxohexanoic acid, and 
1,1,1-trifluoroacetone represented 2-amino-6,6,6-trifluoro-5-oxohexanoic acid. The 
negatively charged red regions of the oxygen atoms became lighter and lighter from left 
to right, which reflects the decreaseing electron densities of the oxygen atoms, and the 
hydrogen bond acceptor abilities of the corresponding carbonyl groups are weakened 
little by little. These EPS surfaces qualitatively showed the relative hydrogen bonding 
strength of these molecules. However, to obtain quantitative results, we needed to 
calculate the binding energies of the hydrogen bonds between serotonin and these model 
molecules. 
 
 
N H
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Figure 4.7 The model system used to calculate the binding energies of the hydrogen 
bonds between the indolic amine of serotonin and Gln analogues. 
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A simple model system was used to mimic the hydrogen bonds between the 
indolic amine of serotoinin and Gln analogues (Figure 4.7). Indole represented serotonin 
and acetone analogues represented Gln analogues. The hydrogen bond binding energy 
was calculated according to the following equation: 
Binding Energy = E(Indole) + E(Molecule) – E(Indole⋅⋅⋅Molecule Complex) 
The calculated total energies (TE) of indole and acetone analogues are 
summarized in Table 4.3. The total energies of the indole⋅⋅⋅molecule complexes are 
shown in Table 4.4. The hydrogen bond binding energies of the model system are 
summarized in Table 4.5. The configurations of the HF/6-31G** optimized 
indole⋅⋅⋅molecule complex structures are shown in Figure 4.8.  
 
Table 4.3 Total energies of indole and acetone analogues. 
TE (Hartree)  
AM1 HF/6-31G** MP2/6-31G** 
Indole 0.0876483 -361.482918 -362.699316 
Acetamide -0.0808907 207.988975 208.611777 
Acetone -0.0784983 -191.972072 -192.571407 
Fluoroacetone -0.1521816 -290.815136 -291.573003 
1,1-difluoroacetone -0.2298946 -389.672355 -390.591911 
1,1,1-trifluoroacetone -0.310967 -488.539615 -489.621864 
 
Table 4.4 Total energies of the indole⋅⋅⋅molecule complexes. 
TE (Hartree) Indole⋅⋅⋅molecule 
complexes AM1 HF/6-31G** MP2/6-31G** 
Acetamide -0.0020535 -569.48447 -571.324855 
Acetone 0.0030624 -553.46438 -555.280201 
Fluoroacetone -0.0700851 -652.306647 -654.280768 
1,1-difluoroacetone -0.1466802 -751.162356 -753.296667 
1,1,1-trifluoroacetone -0.2279992 -850.029096 -852.324389 
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Table 4.5 The hydrogen bond binding energies of the model system, which mimics the 
hydrogen bonds between the indolic amine of serotonin and Gln analogues. 
Binding Energy (kcal/mol) Indole⋅⋅⋅molecule 
complexes AM1 HF/6-31G** MP2/6-31G** 
Acetamide 5.53 7.89 8.64 
Acetone 3.82 5.89 5.95 
Fluoroacetone 3.48 5.39 5.30 
1,1-difluoroacetone 2.78 4.44 3.41 
1,1,1-trifluoroacetone 2.94 4.12 2.01 
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Figure 4.8 The configurations of the HF/6-31G** optimized indole⋅⋅⋅molecule complex 
structures. (a) Indole⋅⋅⋅acetamide complex. (b) Indole⋅⋅⋅acetone complex. (c) 
Indole⋅⋅⋅fluoroacetone complex. (d) Indole⋅⋅⋅difluoroacetone complex. (e) 
Indole⋅⋅⋅trifluoroacetone complex. Red is oxygen, cyan is nitrogen, yellow is fluorine, 
dark yellow is carbon, and white is hydrogen. The numbers are the hydrogen bond 
distances between the oxygen and hydrogen atoms.  
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The hydrogen bond binding energies of the model system decreased from 7.89 
kcal/mol for the acetamide complex to 5.89 kcal/mol for the acetone complex. 
Progressive fluorinations of acetone decreased the binding energies for the corresponding 
complexes little by little. Accordingly, as shown in Figure 4.8, the hydrogen bond 
distance between the oxygen and hydrogen atoms in the acetone complex (2.11 Å) was 
larger than that in the acetamide complex (2.06 Å). Progressive fluorination of acetone 
further increased the hydrogen bond distances little by little. This result agreed with the 
trend seen in the EPS surfaces of the acetone analogues (Figure 4.6). 
The hydrogen binding energies provided a quantitative estimation of the bond 
strength, which could be used for comparison with the experimental results. 
 
 
4.2.2.2 Synthesis of the Asn Analogues to Probe the Hydrogen Bond between Gln 
228 and Serotonin 
Since Asn gave similar responses to Gln at position 228 using all three serotonin 
analogues, for ease of synthesis, we chose to synthesize Asn analogues to probe this 
hydrogen bond. The synthesis of 2-amino-4-oxopentanoic acid and 2-amino-5-fluoro-4-
oxopentanoic acid derivatives is shown in Scheme 4.1.  
  
N-PMP-protected γ-keto-α-amino acid derivatives can be obtained from an L-
proline-catalyzed direct asymmetric Mannich reaction with N-PMP-protected α-
ethylglyoxylate and proper ketone donors.5-7 As shown in step (b) of Scheme 4.1, 3a and 
3b were synthesized with high ee values and good yields according to the reported 
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procedure.7 To obtain high ee values and yields of 3a and 3b, the starting material 2 
needed to be freshly made. The following steps in Scheme 4.1 were not expected to 
introduce significant racemization according to the literature. However, 3a and 3b were 
kept at room temperature for several days, and racemization occurred. Since for nonsense 
unnatural amino acid mutagenesis, only L-amino acids would be incorporated into 
proteins, we did not make further efforts to investigate the chirality of the compounds in 
the following steps. The PMP group was exchanged with a NVOC protection group via a 
one-pot oxidative dearylation and re-protection procedure to afford 4a and 4b.8 The ethyl 
ester  group was removed under mild conditions using potassium carbonate aqueous 
solution to produce 5a and 5b.9, 10 Subsequently, the N-NVOC-protected amino acids 
were activated and coupled to dCA as previously described.11 
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Scheme 4.1 Synthesis of dCA-Asn analogues. Reagents: (a) p-anisidine, CH2Cl2 (93%). 
(b) For 3(a), acetone, L-Pro, DMSO (71%, 91% ee); for 3(b), fluoroacetone, L-Pro, 
DMSO (75%, 98% ee). (c) CAN, H2O/CH3CN; (d) NVOC-Cl, dioxane/H2O; for 4(a), 
61%; for 4(b), 40%. (e) K2CO3, aq. MeOH; for 5(a), 78%; for 5(b), 78%. (f) 
chloroacetonitrile, triethylamine, DMF; for 6(a), 90%; for 6(b), 63%. (g) dCA, DMF.  
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 However, by using the standard L-proline-catalyzed Mannich reaction procedure, 
3c and 3d could not be obtained (Scheme 4.2). The reaction to form 3c was incomplete 
after 48 hours, and it was difficult to separate 3c from starting materials. It was reported 
that the use of the ionic liquid of 1-butyl-3-methylimidazolium tetrafluoroborate 
(BMIMBF4) as the reaction medium could speed up the L-proline catalyzed Mannich 
reaction significantly.12 Therefore, BMIMBF4 was used to perform the reactions again. 
The reaction to form 3c was complete in one hour, and 3c was successfully separated. 
The use of 3c for the following steps to obtain dCA-amino acid is in progress. However, 
3d was not the major product of the corresponding reaction even using BMIMBF4 as the 
reaction medium.  
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Scheme 4.2 Synthesis of N-PMP-protected γ-keto-α-amino acid derivatives. Reagents: (a) 
1,1-difluoroacetone, D,L-Pro, BMIMBF4 (45%); (b) 1,1,1-trifluoroacetone, D,L-Pro, 
BMIMBF4. 
 
 
 Therefore, we needed to design new synthetic routes for 2-amino-5,5,5-trifluoro-
4-oxopentanoic acid derivatives. Several methods have been developed to prepare 
trifluoromethyl ketones from carboxylic acids and carboxylic esters.13-17  
 89
 
H2N
O
O
OH
O
NVOC
N
H O
ONa2CO3
dioxane/H2O
O
OH SOCl2
DMF
CH2Cl2, Py
NVOC-Cl (CF3CO)2O
NVOC
N
H O
O
O
Cl
NVOC
N
H O
O
O
CF3
8 9 10 11
x
 
Scheme 4.3 Failed synthetic route for 2-amino-5,5,5-trifluoro-4-oxopentanoic acid 
derivatives using a carboxylic acid as the starting material.  
 
Starting from a carboxylic acid, we tried the synthetic route shown in Scheme 
4.3.16, 17 However, the key transformation from 10 to 11 did not yield promising results.  
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Scheme 4.4 Proposed synthetic route for 2-amino-5,5,5-trifluoro-4-oxopentanoic acid 
derivatives using a carboxylic ester as the starting material. (a) TMS-CF3 with either 
TBAF or CsF as the initiator. (b) H+. 
 
Starting from carboxylic esters, we proposed another synthetic route shown in 
Scheme 4.4. 13 could be easily obtained from 12 with a high yield (91%).18 Using either 
anhydrous tetrabutylammonium fluoride (TBAF) or cerium fluoride (CsF) as the initiator, 
trifluoromethyltrimethylsilane (TMS-CF3) can be used to transfer a CF3 group to the ester, 
which upon acid hydrolysis, will yield trifluoromethyl ketone.13, 14 It needs to be 
mentioned that in step (a), rigorously dry conditions are a prerequisite for a successful 
reaction. This route seems promising.   
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4.2.2.3 Electrophysiology Recording of the Asn Analogues at Position 228 of MOD-1 
The unnatural Asn analogues obtained above, namely, 2-amino-4-oxopentanoic 
acid (PAO) and 2-amino-5-fluoro-4-oxopentanoic acid (F-PAO), were incorporated into 
position 228 of MOD-1. The recording results using the three serotonin analogues are 
summarized in Table 4.6. The dose-response curves of serotonin on these mutations are 
shown in Figure 4.9. 
 
 
Table 4.6 EC50 values of serotonin analogues for unnatural mutations at position 228 of 
MOD-1.  
Position 228 5-HT Tryptamine BFEA 
EC50 (µM) 10.0±1.2 485±35  
PAO nHill 1.89±0.34 2.75±0.47 
 
NRa 
EC50 (µM) 36±4  
F-PAO nHill 1.68±0.27 
 
NR 
 
NR 
a NR represents no response.  
 
 The substitution of the terminal amine of Asn with a methyl group increased the 
EC50 value of serotonin from 1.19 µM to 10.0 µM. Fluorination of PAO shifted the dose-
response curve further to the right (Figure 4.9 (a)). This trend was in good agreement 
with the calculated hydrogen bond binding energies using the model system (Table 4.5). 
The higher the EC50 values, the smaller the hydrogen boinding energies. We did a plot of 
log (EC50(mutant)/EC50(WT)) versus hydrogen bond binding energy from the HF/6-
31G** calculation, and a good linear fit was found (Figure 4.9 (b)). In combination with 
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previous conventional mutation results (Table 4.2 and Figure 4.5 (a)), the current 
unnatural mutations provide convincing evidence that the terminal amide carbonyl group 
of Gln 288 formed a hydrogen bond.  
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Figure 4.9 Recording results of serotonin on unnatural mutations at position 228 of 
MOD-1. (a) Dose-response curves of serotonin. (b) The correlation between the EC50 
values and the hydrogen bond binding energies. The binding energies are from the HF/6-
31G** results in Table 4.5. 
 
 
EC50 recordings of tryptamine on F-PAO, and BFEA on PAO and F-PAO were 
not successful due to the small currents. By using tryptamine, PAO (485 µM) had a much 
larger EC50 value than Asn (28 µM). Again, this was supportive evidence for the model 
that the actual hydrogen bond partner of Gln 228 is the indolic amine rather than the 
hydroxyl group of serotonin.  
The current results from the unnatural amino acids study together with the 
conventional mutations study unambiguously prove that the terminal amine of Gln forms 
a hydrogen bond with serotonin, and that it is the indolic amine of serotonin that 
participates in this hydrogen bond.  
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In summary, starting from a computational model, a forward and reverse 
pharmacology strategy was applied to evaluate the MOD-1 binding site. Together with 
the powerful unnatural amino acid mutagenesis, the current results represent the most up-
to-date advancement in studying the ligand-binding sites of ion channels. This hydrogen 
bond pattern would not be otherwise elucidated.  
 
 
4.3 Hydrogen Bond between Asn 223 and the Hydroxyl Group of Serotonin 
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Figure 4.10 Structures of conventional mutations made at position 223 of MOD-1. 
 
 
Originally, a strategy similar to what was used in studying Gln 228 was planned 
as follows. To change the hydrogen bonding ability of Asn 223, we mutated asparagine to 
aspartate, glutamine, and alanine (Figure 4.10). We measured the dose-response curves of 
these mutants using serotonin. The results are summarized in Figure 4.11. 
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Figure 4.11 Dose-response curves of serotonin in N223A, N223D, and N223Q mutants 
of MOD-1. 
 
For serotonin, the N223A and N223D mutations gave huge EC50 values (at least 1 
mM), possibly producing a malfunctioning receptor; the N223Q mutant (73 µM) 
increased EC50 about 60-fold. Tryptamine and BFEA were also tried on these three 
mutants. However, either the measured EC50 values were huge (at least 1 mM) or the 
currents were too small to calculate EC50 (data not shown). Although no conclusive result 
was achieved from the experiments, we did find that Asn 223 is very sensitive to 
mutations. Only the Gln mutation was moderately tolerated, possibly due to the 
preservation of the terminal amide group, which was proposed to form a hydrogen bond 
with serotonin in the model.  
We also did some recording on MOD-1 wild type using the drug 5-
methoxytryptamine, and the EC50 value was huge (at least 1mM, data not shown).  
The bottom line was that the present experiments did not disagree with the 
modeling results (Figure 4.1 (b)).  
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4.4 Hydrogen Bond between Main Chain Carbonyl Group of Tyr 180 and the 
Terminal Ammonium of Serotonin 
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Figure 4.12 Structures of serotonin analogues used to probe the hydrogen bond between 
the backbone carbonyl group of Tyr 180 and serotonin. (a) N-Me-serotonin. (b) 
Bufotenin. (c) α-Me-serotonin.  
 
 
Table 4.7 EC50 values of N-Me-serotonin, bufotenin, and α-Me-serotonin in MOD-1 
wild type. 
 N-Me-serotonin Bufotenin α-Me-serotonin 
EC50 (µM) 37±4 10±1 2.8±0.6  
WT nHill 1.0±0.1 1.6±0.3 1.3±0.3 
 
 
Several serotonin analogues were used (Figure 4.12). At first, their EC50 values 
were recorded on wild type MOD-1. The results are shown in Table 4.7. α-Me-serotonin 
had a similar EC50 to wild type, while N-Me-serotonin and bufotenin had much larger 
EC50 values than wild type. N-Me-serotonin has a secondary ammonium, and bufotenin 
has a tertiary ammonium. Therefore, both of these drugs might form a weaker cation-π 
interaction with Trp 226 and also had a weaker hydrogen bond with the backbone 
carbonyl group of Tyr 180 according to our model (Figure 4.1 (c)). The potential 
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hydrogen bonding ability of the terminal ammonium in serotonin could thus be modified 
by using these serotonin analogues. 
 
To modify the hydrogen bonding ability of the main chain carbonyl group of Tyr 
180, we needed to incorporate an α-hydroxy acid into Ser 181. After incorporation, an 
amide-to-ester mutation would appear at the backbone peptide bond between Tyr 180 and 
Ser 181, which could weaken the hydrogen bonding ability of the backbone carbonyl 
group of Tyr 180 (Figure 4.13). This method was successfully used to prove the hydrogen 
bond between nicotine and the backbone carbonyl group of Trp 149 in nAChR,19 which 
was the sequence homolog of Tyr 180 in MOD-1 (Figure 2.4).  
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Figure 4.13 The amide-to-ester mutation to modify the hydrogen bonding ability of the 
backbone carbonyl group of Tyr 180 in MOD-1 with serotonin.   
 
α-Hydroxytyrosine (Yah) was incorporated into Tyr 180 and incorporation of α-
hydroxyserine (Sah) was attempted at Ser 181. Electrophysiology recording was done 
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using serotonin. The incorporation of Yah at position 180 did not significantly change the 
EC50 value (data not shown). Unfortunately, the incorporation of Sah at position 181 did 
not give recordable currents.  
 Although the conclusive result could not be obtained from the current 
experiments, from the EC50 value of N-Me-serotonin in wild type MOD-1 and the result 
that the backbone carbonyl group of the homologous Trp 149 in nAChR forms a 
hydrogen bond with nicotine, it is possible that the hydrogen bond also exists between the 
backbone carbonyl group of Try 180 in MOD-1 and serotonin.  
 
 
4.5 Conclusions and Future Directions 
 
Using the forward and reverse pharmacology strategy, we tested the hydrogen 
bonding pattern of serotonin in MOD-1, which was obtained by the modeling study in 
Chapter 3. The hydrogen bond between the indolic amine group of serotonin and Gln 228 
was confirmed. Our current results showed that it is possible that the two hydrogen bonds 
between serotonin and Asn 223 and the main chain carbonyl group of Tyr 180 exist. 
Therefore, we obtained a high-resolution image of the orientation of serotonin in the 
binding pocket. Moreover, we identified that during the ligand-binding process, both 
cation-π interactions and hydrogen bonds played important roles in directing serotonin to 
the correct orientation inside the binding pocket. If we considered that cation-π 
interactions played a key role in the other Cys-loop superfamily members such as nAChR, 
it is quite possible that in MOD-1, cation-π interactions direct the primary ammonium of 
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serotonin to the proper position with some flexibility to activate the channel, and almost 
simultaneously but a little bit later, the hydrogen bonds between Gln 228/Asn 223 and 
serotonin fix the orientation of serotonin and thus maximize the activation efficiency.  
Future experiments will be focused on finishing the synthesis of 2-amino-5,5-
difluoro-4-oxopentanoic acid and 2-amino-5,5,5-trifluoro-4-oxopentanoic acid. After that, 
they will be incorporated into Gln 228 of MOD-1 for electrophysiology recording, which 
will complete the intended progressive fluorination series.  
Other unnatural amino acids of interest are fluorinated Gln analogues (Figure 
4.14). The synthesis of 4-fluoroglutamine and 4,4-difluoroglutamine were reported.20, 21 
4-fluoroglutamine is also commercially available but expensive. These fluorinated Gln 
analogues are also useful in probing the hydrogen bonding ability of Gln. 
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Figure 4.14 The structures of 4-fluoroglutamine and 4,4-difluoroglutamine.  
 
 
To sum up, by using both computational modeling and a structure-function 
experimental study, especially with the aid of the powerful unnatural amino acid 
mutagenesis method, accurate information on the ligand-binding site and the specific 
non-covalent interactions responsible for the binding process can be obtained even for a 
complicated neuroprotein. With this forward and reverse pharmacology method, more 
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and more progress will be made in the near future while studying the ligand-binding sites 
of neuroreceptors.  
 
 
4.6 Materials and Methods 
4.6.1 Electrophysiology 
 Electrophysiological recordings were made 24–72 hours after injection. Whole-
cell currents from stage VI oocytes of Xenopus laevis were measured in standard two-
electrode voltage clamp mode using the OpusXpressTM 6000A (Axon Instruments, Union 
City, California). Microelectrodes were filled with 3M KCl and the resistances were 
between 0.5 and 2 MΩ. Oocytes were continuously perfused with calcium-free ND96 or 
ND96 bath solution at flow rates of 1 ml/min, 4 ml/min during drug application and 3 
ml/ml during wash. The holding potential was -60 or -80 mV. Data were sampled at 125 
Hz and filtered at 50 Hz. Drug applications were 15 s. Serotonin was purchased from 
Sigma/Aldrich and all drugs were prepared in ND96 solution. Dose-response data were 
obtained from 3 to 5 oocytes and data were reported as mean ± standard error. Curves 
were fit to the Hill equation, I/Imax = 1/[1 + (EC50/[A])nH], where I is the current for 
agonist concentration [A], Imax is the maximum current, EC50 is the concentration to elicit 
a half-maximum response, and nH is the Hill coefficient.  
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4.6.2 Incorporation of Unnatural Amino Acids by in vivo Nonsense Suppression 
Methods 
For suppression experiments, 25 ng of tRNA and 10 ng of mRNA were co-
injected in a total volume of 50 nL per oocyte. Immediately before microinjection, the 
NVOC-aminoacyl-tRNA was deprotected by photolysis. The ligation of aminoacyl-dCA 
to tRNA and gene construction of suppressor tRNA have been described previously. The 
MOD-1 gene was subcloned into the plasmid pBlueScript. The MOD-1 TAG mutants 
were made by the QuickchangeTM site-directed mutagenesis method and were monitored 
by DNA sequencing. Plasmid DNAs were linearized with KpnI, and mRNA was 
transcribed using the Ambion T3 mMESSAGE mMACHINE kit.  
 For wild type and conventional mutation experiments, only 5 ng mRNA was 
injected into oocytes in a 50 nL volume per cell with the same following procedure as 
described above.  
 dCA-α-hydroxyserine was a gift from Niki M. Zacharias at Neurion 
Pharmaceuticals.  
 
4.6.3 Synthesis of Amino Acids, dCA-Amino Acid and Others 
4.6.3.1 General 
Reagents were purchased from Aldrich, Sigma, or other commercial sources. 
Flash chromatography was on 230–400 mesh silica gel with the solvent indicated. All 
NMR shifts are reported as δ ppm downfield from TMS. 1H (300 MHz) and 19F (282 
MHz) NMR spectra were recorded using a GE QE-300 or Varian 300 spectrometer. 
Electrospray ionization (ESI) mass spectrometry was performed at the Caltech 
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Protein/Peptide Micro Analytical Laboratory. High performance liquid chromatography 
(HPLC) separations were performed on a Waters dual 510 pump liquid chromatography 
system equipped with a Waters 996 PDA (photodiode array) UV detector for semi-
preparative HPLC. Waters Prep Nova-Pak HR C18 column (7.8x300 mm) was used for 
semi-preparative HPLC.  
 
4.6.3.2 Synthesis of 2-Amino-4-Oxopentanoic Acid, 2-Amino-5-Fluoro-4-
Oxopentanoic Acid, and 2-Amino-5,5-Difluoro-4-Oxopentanoic Acid 
The synthetic routes are shown in Scheme 4.1 and Scheme 4.2.  
 
N-(Ethoxycarbonylmethylidine)-4-methoxyaniline (2). 5.089 ml of the ethyl 
glyoxylate solution (1) (50% v/v in toluene, 25 mmol) and 2 g of anhydrous Na2SO4 were 
added in 30 ml of CH2Cl2 at 0 °C. 3.079 g of p-anisidine (25 mmol) was added to the 
solution. The mixture was stirred under argon for 5 minutes at 0 °C and another 2 hours 
at room temperature. The reaction was quenched by the addition of 20 ml of CH2Cl2, 
dried over Na2SO4, and rotary-evaporated. Flash chromatography (1:3 ethyl acetate / 
petroleum ether) gave 4.817 g (93%) of product as a yellow oil.  1H NMR (CDCl3) δ = 
1.36 (t, 3H), 3.78 (s, 3H), 4.36 (q, 2H), 6.88 (d, 2H), 7.32 (d, 2H), 7.89 (s, 1H). ESI-MS 
calcd for C11H13NO3: 207.09. Found [M+H]+: 208.0. 
 
Ethyl (2S)-2-(p-methoxyphenylamino)-4-oxopentanoate (3a). 3.105 g of 2 (15 
mmol) was dissolved in 120 ml of anhydrous DMSO. 30 ml of acetone was added 
followed by 345 mg of L-proline (3 mmol, 20 mol%). The mixture was stirred under 
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argon for 18 hours at room temperature. The reaction was quenched by the addition of 
150 ml of half-saturated ammonium chloride solution, and extracted with ethyl acetate 
(150 ml x 2, 100 ml, 50 ml). The combined organic layer was dried over Na2SO4, and 
rotary-evaporated. Flash chromatography (1:1 ethyl acetate / petroleum ether) gave 2.818 
g (71%) of product as a yellow oil. Chiral HPLC (Daicel Chiralpak AD column, hexane / 
i-PrOH = 96:4, flow rate 1 ml/min, λ = 254 nm): tR (major) = 46.30 min; tR (minor) = 
43.75 min; ee = 91%. 1H NMR (CDCl3) δ = 1.22 (t, 3H), 2.18 (s, 3H), 2.96 (d, 2H), 3.74 
(s, 3H), 4.17 (q, 2H), 4.33 (t, 1H), 6.64 (d, 2H), 6.77 (d, 2H). ESI-MS calcd for 
C14H19NO4: 265.13. Found [M+H]+: 266.0, [M+Na]+: 287.8, [M+K]+: 303.8. 
 
Ethyl (2S)-5-fluoro-2-(p-methoxyphenylamino)-4-oxopentanoate (3b). 1.700 g 
of 2 (8.2 mmol) was dissolved in 60 ml of anhydrous DMSO. 15 ml of fluoroacetone was 
added followed by 189 mg of L-proline (1.64 mmol, 20 mol%). The mixture was stirred 
under argon for 26 hours at room temperature. The reaction was quenched by the addition 
of 75 ml of half-saturated ammonium chloride solution, extracted with ethyl acetate (75 
ml x 2, 50 ml, 25 ml). The combined organic layer was dried over Na2SO4, and rotary-
evaporated. Flash chromatography (1:1 ethyl acetate / petroleum ether) gave 1.729 g 
(75%) of product as a yellow oil. Chiral HPLC (Daicel Chiralpak AS column, hexane / i-
PrOH = 90:10, flow rate 1 ml/min, λ = 254 nm): tR (major) = 32.20 min; tR (minor) = 
44.99 min; ee = 98%. 1H NMR (CDCl3) δ = 1.24 (t, 3H), 3.07 (m, 2H), 3.74 (s, 3H), 4.19 
(q, 2H), 4.44 (t, 1H), 4.83 (d, 2H, J = 47.4 Hz), 6.67 (d, 2H), 6.77 (d, 2H). 19F NMR 
(CDCl3) δ = 2.51 (t, 1F, J = 47.4 Hz). ESI-MS calcd for C14H18FNO4: 283.12. Found 
[M+H]+: 283.8, [M+Na]+: 305.8.  
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Ethyl 5,5-difluoro-2-(p-methoxyphenylamino)-4-oxopentanoate (3c). 4.5 ml of 
1,1-difluoroacetone and 173 mg of D,L-proline (1.5 mmol, 60 mol%) were added in 2 ml 
of the ionic liquid of 1-butyl-3-methylimidazolium tetrafluoroborate (BMIMBF4). The 
mixture was stirred under argon for 20 minutes at room termperature. 518 mg of 2 (2.5 
mmol) in 2.5 ml of BMIMBF4 was added. The reaction was stirred under argon for 2 
hours at room temperature. The reaction was extracted with ethyl ether (20 ml x 4). The 
combined ether layer was rotary-evaporated. Flash chromatography (1:2 ethyl acetate / 
petroleum ether) gave 337 mg (45%) of product as a brown oil. 1H NMR (CDCl3) δ = 
1.24 (t, 3H), 3.17 (d, 2H), 3.74 (s, 3H), 4.19 (q, 2H), 4.45 (t, 1H), 5.73 (t, 1H, J = 53.8 
Hz), 6.67 (d, 2H), 6.77 (d, 2H). 19F NMR (CDCl3) δ = -127.61 (d, 2F, J = 53.5 Hz). ESI-
MS calcd for C14H17F2NO4: 301.11. Found [M+H]+: 302.0.  
 
Ethyl 2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-4-oxopentanoate 
(4a). 265 mg of 3a (1 mmol) in 10 ml of CH3CN was stirred at 0 °C. 1.645 g of CAN (3 
mmol) in 10 ml of H2O was added dropwise. The reaction was stirred under argon for 1 
hour at 0 °C. The mixture was neutralized using saturated NaHCO3 aq to pH around 7.0, 
rotary-evaporated briefly to remove CH3CN. To the remaining mixture was added 
Na2S2O3 (316 mg, 2 mmol) and Na2CO3 (160 mg, 1.5 mmol). 276 mg of 2-
nitroveratryloxycarbonyl chloride (NVOC-Cl) (1 mmol) in 20 ml of p-dioxane was added. 
The reaction was stirred under argon for 4 hours at room temperature. The mixture was 
extracted with CH2Cl2 (20 ml x 2, 10 ml x 3). The combined organic layer was decolored 
by activated carbon, filtrated through Celite, dried over Na2SO4, and rotary-evaporated. 
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Flash chromatography (1:1 ethyl acetate / petroleum ether) gave 243 mg (61%) of 
product as a pale-yellow solid. Chiral HPLC (Daicel Chiralpak AS column, hexane / 
ethanol = 90:10, flow rate 1 ml/min, λ = 254 nm): tR (major) = 36.67 min; tR (minor) = 
44.15 min; ee = 5 %, which was mainly due to the use of racemized 3a. 1H NMR (CDCl3) 
δ = 1.24 (t, 3H), 2.18 (s, 3H), 3.00 (dd, 1H), 3.25 (dd, 1H), 3.95 (s, 3H), 4.01 (s, 3H), 
4.18 (q, 2H), 4.52 (m, 1H), 5.47 and 5.60 (AB, 2H), 5.91 (d, 1H), 7.04 (s, 1H), 7.71 (s, 
1H). ESI-MS calcd for C17H22N2O9: 398.13. Found [M+H]+: 398.8, [M+Na]+: 420.8, 
[M+K]+: 436.8. 
 
Ethyl 2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-5-fluoro-4-
oxopentanoate (4b). 567 mg of racemized 3b (2 mmol) in 20 ml of CH3CN was stirred 
at 0 °C. 3.290 g of CAN (6 mmol) in 20 ml of H2O was added dropwise. The reaction 
was stirred under argon for 1 hour at 0 °C. The mixture was neutralized using saturated 
NaHCO3 aq to pH around 7.0, rotary-evaporated briefly to remove CH3CN. To the 
remaining mixture was added Na2S2O3 (632 mg, 4 mmol) and Na2CO3 (318 mg, 3 mmol). 
551 mg of NVOC-Cl (2 mmol) in 40 ml of p-dioxane was added. The reaction was stirred 
under argon for 4 hours at room temperature. The mixture was extracted with CH2Cl2 (40 
ml x 2, 20 ml x 3). The combined organic layer was decolored by activated carbon, 
filtrated through Celite, dried over Na2SO4, and rotary-evaporated. Flash chromatography 
(1:1 ethyl acetate / petroleum ether) gave 330 mg (40%) of product as a pale-yellow 
powder. 1H NMR (CDCl3) δ = 1.25 (t, 3H), 3.15 (m, 1H), 3.31 (m, 1H), 3.95 (s, 3H), 4.01 
(s, 3H), 4.67 (m, 1H), 4.82 (d, 1H, J = 48.0 Hz), 5.47 and 5.59 (AB, 2H), 5.84 (d, 1H), 
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7.03 (s, 1H), 7.71 (s, 1H). 19F NMR (CDCl3) δ = 1.49 (t, 1F, J = 47.7 Hz). ESI-MS calcd 
for C17H21FN2O9: 416.12. Found [M+H]+: 416.8, [M+Na]+: 439.0, [M+K]+: 455.0. 
 
2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-4-oxopentanoic acid 
(5a). 180 mg of 4a (0.45 mmol) in 2.3 ml of methanol and 125 mg of K2CO3 (0.90 mmol) 
in 1.1 ml of H2O were stirred at room temperature for 10 hours. The reaction was poured 
into 5.6 ml of H2O, washed with ethyl ether (5 ml x 3). The aqueous layer was acidified 
with 6 N HCl until the product began to precipitate (pH around 2.0). The resulting cloudy 
solution was stored in the 4 °C frig overnight. After vacuum filtration, the solid was 
collected as one portion of the product; the filtered solution was extracted with ethyl 
acetate (15 ml x 3), and the combined organic layer was dried over Na2SO4, and rotary-
evaporated to yield the other portion of the product. Altogether, 129 mg (78%) of the 
product was obtained as a pale-yellow powder. 1H NMR (d6-DMSO) δ = 2.10 (s, 3H), 
2.87 (m, 2H), 3.85 (s, 3H), 3.90 (s, 3H), 4.37 (m, 1H), 5.34 (m, 2H), 7.13 (s, 1H), 7.69 (s, 
1H), 7.78 (d, 1H). ESI-MS calcd for C15H18N2O9: 370.10. Found [M+Na]+: 392.8, 
[M+K]+: 408.8. 
 
2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-5-fluoro-4-oxopentanoic 
acid (5b). Prepared as the procedure described above except using 4b as the starting 
material. Yield: 78%. 1H NMR (d6-DMSO) δ = 2.10 (s, 3H), 2.86 (m, 2H), 3.85 (s, 3H), 
3.90 (s, 3H), 4.39 (m, 1H), 5.04 (d, 2H, J = 46.8 Hz), 5.35 (m, 2H), 7.12 (s, 1H), 7.69 (s, 
1H), 7.86 (d, 1H). 19F NMR (d6-DMSO) δ = 1.58 (t, 1F, J = 47.5 Hz). ESI-MS calcd for 
C15H17FN2O9: 388.09. Found [M+Na]+: 411.0, [M+K]+: 426.8, [M-H]-: 387.0. 
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Cyanomethyl 2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-4-
oxopentanoate (6a). 73 mg of 5a (0.20 mmol) was dissolved in 5 ml of DMF. 380 µl of 
chloroacetonitrile (6.0 mmol) and 105 µl of triethylamine (0.75 mmol) were added. The 
mixture was stirred under argon at room temperature for 10 hours. The reaction was 
quenched with 10 ml of 0.1 M KH2PO4 and 20 ml of H2O, extracted with ethyl acetate 
(40 ml, 30 ml x 2). The combined organic layer was washed with 50 ml of H2O, dried 
over Na2SO4, and rotary-evaporated. Flash chromatography (4:1 ethyl acetate / petroleum 
ether) gave 78 mg (90%) of product as a pale-yellow powder. 1H NMR (CDCl3) δ = 2.21 
(s, 3H), 3.07 (dd, 1H), 3.30 (dd, 1H), 3.96 (s, 3H), 4.02 (s, 3H), 4.67 (m, 1H), 4.76 (s, 
2H), 5.47 and 5.62 (AB, 2H), 5.83 (d, 1H), 7.02 (s, 1H), 7.72 (s, 1H). ESI-MS calcd for 
C17H19N3O9: 409.11. Found [M+Na]+: 432.0, [M+K]+: 447.8. 
 
Cyanomethyl 2-((4,5-dimethoxy-2-nitrobenzyloxy)carbonylamino)-5-fluoro-
4-oxopentanoate (6b). Prepared as the procedure described above except using 5b as the 
starting material. Yield: 63%. 1H NMR (d6-DMSO) δ = 2.96 (m, 2H), 3.86 (s, 3H), 3.90 
(s, 3H), 4.58 (m, 1H), 5.01 (s, 2H), 5.06 (d, 2H, J = 46.3 Hz), 5.36 (s, 2H), 7.13 (s, 1H), 
7.69 (s, 1H), 8.09 (d, 1H). 19F NMR (d6-DMSO) δ = 1.22 (t, 1F, J = 45.5 Hz). ESI-MS 
calcd for C17H18FN3O9: 427.10. Found [M+Na]+: 449.8, [M+K]+: 465.8, [M+Cl’]-: 462.0. 
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4.6.3.3 Synthesis of NVOC-Gln Cyanomethyl Ester 
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Scheme 4.5 Synthesis of NVOC-Gln cyanomethyl ester. 
 
 
NVOC-Gln. 219 mg (1.5 mmol) of glutamine in 15 ml of p-dioxane and 238 mg 
(2.25 mmol, 1.5 eq) of Na2CO3 in 20 ml of water were stirred at room temperature. 413 
mg (1.5 mmol) of NVOC-Cl in 15 ml of p-dioxane was added dropwise. The reaction 
was stirred at room temperature for 1 hour. The mixture was poured into 50 ml of H2O, 
washed with ethyl ether (50 ml x 3). The aqueous layer was acidified with 6 N HCl until 
the product began to precipitate (pH around 2.0). The resulting cloudy solution was 
stored in the 4 °C refrigerator overnight. The crude crystals were collected by vacuum 
filtration, and afterward, recrystallized by using 1:1 H2O / MeOH. 486 mg (84%) of 
product was obtained as a pale-yellow crystal. 1H NMR (d6-DMSO) δ = 1.77 (m, 1H), 
1.99 (m, 1H), 2.19 (t, 2H), 3.89 (s, 3H), 3.95 (s, 3H), 4.00 (m, 1H), 5.40 (m, 2H), 6.79 (s, 
1H), 7.21 (s, 1H), 7.31 (s, 1H), 7.74 (s, 1H), 7.88 (d, 1H).  
 
NVOC-Gln cyanomethyl ester. 83 mg of NVOC-Gln (0.22 mmol) was dissolved 
in 4 ml of DMF. 418 µl of chloroacetonitrile (6.6 mmol) and 93 µl of triethylamine (0.66 
mmol) were added. The mixture was stirred under argon at room temperature for 10 
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hours. The reaction was quenched with 10 ml of 0.1 M KH2PO4 and 15 ml of H2O, 
extracted with ethyl acetate (30 ml x 2, 20 ml). The combined organic layer was washed 
with H2O (30 ml x 2), dried over Na2SO4, and rotary-evaporated. Flash chromatography 
(pure ethyl acetate) gave 90 mg (93%) of product as a pale-yellow solid. 1H NMR (d6-
DMSO) δ = 1.80 (m, 1H), 1.99 (m, 1H), 2.18 (t, 2H), 3.86 (s, 3H), 3.91 (s, 3H), 4.15 (m, 
1H), 5.01 (s, 2H), 5.36 (m, 2H), 6.80 (s, 1H), 7.17 (s, 1H), 7.30 (s, 1H), 7.70 (s, 1H), 8.11 
(d, 1H). ESI-MS calcd for C17H20N4O9: 424.12. Found [M+H]+: 425.0, [M+Na]+: 446.8, 
[M+K]+: 462.8. 
 
4.6.3.4 General procedure for coupling of N- NVOC-protected amino acid 
cyanomethyl esters to dCA 
 
Scheme 4.6 General procedure for coupling of amino acids to dCA. 
 
The N-protected amino acid cyanomethyl ester (~30 µmol, 3 equivalents) was 
mixed with the tetrabutylammonium salt of the dCA dinucleotide (~10 µmol, 1 
equivalent) in 400 µl of dry DMF. The reaction mixture was kept stirring for 3–5 hours 
under argon. The reaction was monitored by reverse-phase analytical HPLC with a 
gradient from 25 mM ammonium acetate (pH 4.5) to CH3CN. The crude product was 
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isolated using reverse-phase semi-preparative HPLC. The desired fractions containing the 
aminoacyl dinucleotide were combined, frozen, and lyophilized. The lyophilized solid 
was redissolved in 3:2 10 mM aqueous acetic acid / acetonitrile and lyophilized a second 
time to remove ammonium ions, which inhibit T4 RNA ligase in the ligation of dCA-
amino acid to the tRNA. The products were characterized by mass spectrometry and 
quantified by UV / Vis spectra, assuming ε350 ~ 6336 per nitroveratryl group.  
 
dCA-NVOC-2-amino-4-oxopentanoic acid (7a). Prepared as above using 6a as 
the starting material. ESI-MS calcd for C34H42N10O21P2: 988.20. Found [M-H]-: 987.2, 
[M+Na-2H]-: 1009.2, [M-NVOC]-: 761.2. 
 
dCA-NVOC-2-amino-5-fluoro-4-oxopentanoic acid (7b). Prepared as above 
using 6b as the starting material. ESI-MS calcd for C34H41FN10O21P2: 1006.19. Found 
[M-H]-: 1005.2, [M-NVOC]-: 775.2. 
 
dCA-NVOC-Gln (7b). Prepared as above using NVOC-Gln cyanomethyl ester as 
the starting material. ESI-MS calcd for C34H43N11O21P2: 1003.21. Found [M-H]-: 1002.2. 
 
4.6.3.5 Synthesis of 2-(benzofuran-3-yl)ethylamine (BFEA) 
 
 
C N AlLiH4
ether
O O
NH2
 
 
Scheme 4.7 Synthesis of 2-(benzofuran-3-yl)ethylamine. 
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2-(benzofuran-3-yl)ethylamine. 126 mg of LiAlH4 (3.31 mmol, 1.3 eq) in 14 ml 
of anhydrous ether was stirred under argon at room temperature for 20 minutes. 400 mg 
of 2-(benzofuran-3-yl)acetonitrile (2.54 mmol, 1eq) in 5 ml of ether was added dropwise. 
The mixture was stirred under argon at room temperature for 10 hours. The reaction was 
quenched by the careful addition of 1 ml of saturated Na2SO4 aqueous solution dropwise 
at 0 °C, decanted, and extracted with ether (10 ml, 4 ml x 5). The combined organic layer 
was dried over Na2SO4, and rotary-evaporated. Flash chromatography (15:85 to 50:50 
methanol / ethyl acetate with 1% triethylamine) gave 226 mg (55%) of product as a 
yellow oil. 1H NMR (CDCl3) δ = 2.89 (t, 2H), 3.09 (t, 2H), 7.30 (m, 2H), 7.50 (m, 2H), 
7.59 (s, 1H). ESI-MS calcd for C10H11NO: 161.08. Found [M+H]+: 162.1. 
 
 
 
4.6.4 Computational Methods 
All the calculations were performed in gas phase with the Gaussian 98 software.22 
The model system used was shown in Figure 4.7. Indole, and all the acetone analogues 
were optimized by AM1, HF/6-31G**, and MP2/6-31G**, respectively.  
The hydrogen bond binding energy was calculated according to the following 
equation: 
Binding Energy = E(Indole) + E(Molecule) – E(Indole⋅⋅⋅Molecule Complex) 
The indole⋅⋅⋅acetone complex was optimized by HF/6-31G** using seven 
different starting configurations, which varied the hydrogen bond angles and other related 
factors. The optimal indole⋅⋅⋅acetone structure was chosen from the one with the lowest 
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binding energy. All the other indole⋅⋅⋅molecule complexes were built based on the 
optimal indole⋅⋅⋅acetone structure and optimized by HF/6-31G**. AM1 optimizations and 
MP2/6-31G** single point energy calculations were performed on the HF/6-31G** 
optimized indole⋅⋅⋅molecule complexes. The hydrogen bond binding energies were then 
obtained according to the above equation at the AM1, HF/6-31G**, and MP2/6-31G** 
levels.  
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Chapter 5 
 
 
 
Tethered Agonist Approach to Map the Ligand-Binding  
Site of MOD-1 
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5.1 Introduction 
 
Several tethered agonist strategies have been developed to probe the ligand-
binding site in nAChR. The chemical modification of Cys residues was introduced by 
Karlin and co-workers, and further used by the Lester group and the Cohen lab.1-3 
However, this method depends on cysteine modification. If the Cys mutation is not 
functional or the modification reaction is not efficient, this method may not be a good 
choice. Another strategy to introduce tethered agonists is to directly incorporate the 
desired tethers at the site of interest using the powerful unnatural amino acid mutagenesis 
methodology.4 Different tethers can be used to probe different sites, including those that 
are not accessible by external reagents. In the following, we will discuss the tethered 
agonist strategy by using the unnatural amino acid mutagenesis method.  
   
 
 (b) (a) 
 
 
 
 
 
 
Figure 5.1 The tethered agonist approach to map the acetylcholine (ACh) binding site in 
nAChR. (a) Incorporation of Tyr-O3Q at position 149 to mimic the natural agonist. (b) 
Spontaneously opening channel blocked by the open channel blocker TMB-8. 
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Tyrosine derived tethered agonists were used in nAChR.5, 6 As in Figure 5.1, the 
quaternary ammonium of acetylcholine (ACh) is positioned over the six-member ring of 
Trp 149. Incorporation of the unnatural amino acid Tyr-O3Q (see Figure 5.1 for the 
structure) at position 149 can deliver the quaternary ammonium to the same position as 
the natural agonist ACh. Therefore, Tyr-O3Q will mimic the behavior of ACh, produce a 
constitutively active receptor, and give standing currents without the addition of external 
agonists. The constitutively active channel can be blocked by the addition of a channel 
blocker, such as TMB-8. It should be pointed out that the tethered agonist can be viewed 
as a weak partial agonist. Therefore, the addition of acetylcholine can induce more 
current. The efficiency of the tethered agonists is expressed by the ratio of the 
constitutively opening current that is blocked by TMB-8 (labeled as b in Figure 5.1 (b)) 
to the ACh induced current (labeled as c in Figure 5.1 (b)). The larger the ratio of b/c, the 
more effective the tethered agonist. Several tethers with different lengths were 
incorporated into several positions near the binding site. Tyr-O3Q seemed to have the 
optimal length at position 149 and gave the highest efficiency. Later, the tethered agonist 
approach was applied to study the pH effect on the binding site in nAChR.7 
 
 
 
 
 
 
Figure 5.2 Tethered agonists used in MOD-1. 
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 In this chapter, we applied this strategy to further map the ligand-binding site of 
MOD-1. Serotonin has a primary ammonium instead of the quaternary ammonium of 
ACh. Therefore, we incorporated both Try-O3P to mimic the primary ammonium and 
Tyr-O3Q to mimic the quaternary ammonium at the sites of interest in MOD-1 (Figure 
5.2). From previous studies we know that the primary ammonium of serotonin is 
positioned over the six-member ring of Trp 226 in MOD-1. Also Tyr 180 is near the 
binding site. These two sites were chosen for a detailed study. Other sites near the 
binding sites were also tried. The results show that the incorporation of Tyr-O3P at 
position 226 yields the highest efficiency, which is in agreement with our previous 
experiments.  
 
 
5.2 Effect of the Channel Blocker Picrotoxin on MOD-1 
 
Before performing the tethered agonist experiments in the MOD-1 receptor, we 
need to have some knowledge on the following two aspects.  
First, since the tethered agonist is a weak partial agonist, in order to observe the 
constitutively opening current after incorporation, the ion pore needs to be made to open 
more easily.  
Second, we need to find a proper channel blocker. This blocker should not be near 
the agonist-binding site so that the incorporation of the tethered agonists will not affect 
the blockage behavior of this blocker.  
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To make the ion pore open more easily, from the study of nAChR, mutations at 
the Leu 9’ position in the M2 region are good choices (Figure 5.3 (a)).8, 9 Therefore, we 
made the Val, Ala, Ser, and Thr mutations at the Leu 9’ position in the M2 region of 
MOD-1. The results are shown in Table 2.1 and Figure 5.3 (b).  
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(b) (a) 
Figure 5.3 The effect of L9’ mutations on channel gating. (a) Structure of nAChR. 
Adapted from Ref8. (b) Dose-response curves of some L9’ mutations in MOD-1. 
 
 
Table 5.1 EC50 of L9’ mutations in MOD-1 using serotonin.  
 EC50 (nM) nHill 
WT 1220 ± 300 1.2 ± 0.3 
L9’T 41 ± 9 1.4 ± 0.3 
L9’S 33 ± 3 0.9 ± 0.1 
L9’A 65 ± 11 1.1 ± 0.2 
L9’V 1090 ± 200 1.5 ± 0.3 
 
It can be seen that L9’T, L9’S, and L9’A mutants are much more sensitive to 
serotonin than wild type, while the L9’V mutant is similar to wild type. Therefore, L9’T, 
L9’S, and L9’A mutants were further tested for their blockage behaviors. 
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Some drugs were tested for their ability to block the wild type channel. These 
drugs included mianserin, an antagonist of MOD-1; picrotoxin, picrotoxinin, and 
penicillin G, the GABAA receptor blockers; and R(+)-IAA94, a potent chloride channel 
blocker. Penicillin G and R(+)-IAA94 did not block the channel; although mianserin 
blocked the channel efficiently, most possibly it acted as a competitive antagonist and did 
not meet our criteria for tethered agonist experiments; picrotoxinin had slightly lower 
blockage efficiency than picrotoxin. Therefore, we chose picrotoxin (IC50 is about 500 
µM with the application of 1 µM serotonin on wild type) as the channel blocker in the 
following experiments. 
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(a) (b) 
Figure 5.4 Picrotoxin blockage effect on wild type and L9’ mutant MOD-1s. (a) The 
typical experimental procedure and representative traces. (b) Summary of the picrotoxin 
blockage effect. The three data groups are for the application of picrotoxin at three 
different concentrations (30 µM, 300 µM, or 3000 µM). All the columns with positive 
values correspond to the d/c ratios; all the columns with negative values correspond to 
the b/c ratios. 
 
  
 We tested the picrotoxin effect on wild type and L9’T, L9’S and L9’A mutant 
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MOD-1s. The typical procedure and representative traces are shown in Figure 5.4 (a). 
First, 5-HT at the near EC50 concentration (1 µM for wild type or 50 nM for all the 
mutants) was applied and the resulting inward current was recorded as a positive value c. 
Then picrotoxin (PTX) at different concentrations (30 µM, 300 µM, or 3000 µM) was 
applied and the resulting outward current was recorded as a negative value b; this 
outward current occurs because the channel is spontaneously opening and thus is blocked 
by picrotoxin. Finally, 5-HT together with PTX was applied and the resulting inward 
current was recorded as a positive value d. The ratios of b/c and d/c at different 
picrotoxin concentrations for either wild type or the mutants are summarized in Figure 
5.4 (b). There are three groups of data; each group corresponds to the application of 
picrotoxin at one concentration. All the columns with positive values correspond to the 
d/c ratios; all the columns with negative values correspond to the b/c ratios.  
 From Figure 5.4, we can see that picrotoxin at 300 µM can efficiently block the 
wild type and L9’T mutant. However, all the mutants also produce spontaneously 
opening channels, and the constitutively opening current can be blocked by picrotoxin 
even before introduction of the tethered agonists (Figure 5.4). Therefore, we need to 
perform this control experiment when we incorporate the tethered agonists at the site of 
interest. Since the L9’T mutant can be blocked by picrotoxin efficiently, the tethered 
agonists would be incorporated at the sites of interest into this construct unless otherwise 
stated. 
 
5.3 Tethered Agonist Experiments in MOD-1 
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Using the construct with L9’T mutations in the M2 region, we tried to incorporate 
Tyr-O3P and Tyr-O3Q into the sites of Trp 226 in loop C and Try 180 in loop B. 
However, we did not find any spontaneously opening current even with the application of 
3 mM picrotoxin.  
Using the construct without L9’T mutations in the M2 region, we tried to put Try-
O3P into the sites of Phe 83 in loop D, Try 180 and Trp 191 in loop B, and Try 221 and 
Trp 226 in loop C, and Try-O3Q into the sites of Try 180 in loop B, and Trp 226 in loop 
C. Again, we did not find any spontaneously opening current even with the application of 
3 mM picrotoxin.  
The above results seemed puzzling. However, we know that MOD-1 is a 
homopentamer. The incorporation of five Tyr-O3P or Tyr-O3Q into each receptor 
probably will not be successful or produce non-functional receptors. In order to 
incorporate less Try-O3P or Tyr-O3Q into each receptor, we could simultaneously 
incorporate some wild type amino acids at the site of interest. Therefore, we tried to 
inject tRNA mixtures and adjust their ratio. For example, to incorporate less Tyr-O3P 
into the site of Trp 226, we tried to inject both tRNA-Trp and tRNA-Tyr-O3P and vary 
their ratios. Our experiments showed that this strategy worked well. Constitutively active 
channels were found using the construct with L9’T mutations in the M2 region, which 
could be blocked by picrotoxin. The ratio of 1:1 tRNA mixtures yielded the optimal 
result (data not shown). Therefore, in the following experiments, we used tRNA mixtures 
with the ratio of 1:1 to incorporate corresponding tethered agonists unless otherwise 
noted. 
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Figure 5.5 Tethered agonist experiments at position 226 of MOD-1. (a) Representative 
electrophysiology recording traces. (b) Results from the recording with ND96 solution. (c) 
Results from the recording with Ca2+-free ND96 solution. 
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Figure 5.6 Tethered agonist experiments at position 180 of MOD-1. (a) Results from the 
recording with ND96 solution. (b) Results with Ca2+-free ND96 solution recordings. 
 122
Using the 1:1 tRNA mixtures and the construct with L9’T mutations in the M2 
region, again, we tried to incorporate Tyr-O3P and Tyr-O3Q into the sites of Trp 226 in 
loop C and Try 180 in loop B. The control experiments on uninjected oocytes and wild 
type with L9’T mutations were also conducted. The typical experimental procedure and 
electrophysiology recording traces are shown in Figure 5.6 (a). 5-HT (1 µM) was applied 
and the resulting inward current was recorded as a positive number c; then picrotoxin (1 
mM) was applied and the resulting outward current was recorded as a negative number b. 
Current amplitudes at position 226 and position 180 are summarized in Figure 5.6 and 
Figure 5.7, respectively. The effect of Ca2+ was also considered in the experiment. The 
efficiencies of the tethered agonists were measured using the absolute values of the b/c 
ratio. The results are summarized in Figure 5.8.  
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Figure 5.7 Efficiencies of tethered agonists in MOD-1. (a) Recorded with ND96 solution. 
(b) Recorded with Ca2+-free ND96 solution. 
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 It can be seen that the results from the recordings with ND96 solution are similar 
to but better than those with Ca2+-free ND96 solution (Figure 5.7). The tethered agonists 
Tyr-O3P and Tyr-O3Q both have higher efficiency at position 226 than at position 180. 
Tyr-O3P is more efficient than Try-O3Q at both position 226 and position 180. Since 
serotonin owns a primary ammonium that is above Trp 226 in MOD-1, it can be 
imagined that the incorporation of Tyr-O3P at position 226 gives the highest efficiency, 
which is the case in our tethered agonist experiments. However, the highest efficiency we 
obtained is about 0.7. If we considered that the application of Tyr-O-3Q at Trp 149 in 
nAChR could achieve an efficiency value of about 7, our current tethered agonist 
experiments in MOD-1 seemed to yield low efficiency.  
  
 
5.4 Conclusions 
We applied the tethered agonist approach to further map the ligand-binding site of 
MOD-1. Try-O3P and Tyr-O3Q were used to probe the sites of Trp 226 and Tyr 180. 
Current results agreed with our previous experiments. 
However, the efficiency of the tethered agonists in MOD-1 was low. There are 
several possibilities for this low efficiency. First, the tethered agonists used here are not a 
perfect mimic of serotonin. From Chapter 4, we know that serotonin also contacts other 
residues by hydrogen bonds. But here, we just ignored those parts of serotonin. Not 
surprisingly, this should have some effect on binding. Second, since MOD-1 is a 
homopentamer, the incorporation of five tethered agonists into the specific position may 
be difficult. Although we used the tRNA mixtures to solve this problem, it is possible that 
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this solution is not optimal. To date only one subunit of MOD-1 has been found. If 
another subunit can be found to form stable heteropentamers with the current one, we can 
use the heteropentamer for the incorporation of the proper amount of tethered agonists 
into one receptor with more confidence. Third, picrotoxin may not be the best channel 
blocker used for this purpose because it is not very potent in MOD-1. The spontaneously 
opening currents may be underestimated by using picrotoxin. It may be possible to 
achieve higher efficiency by using other proper blockers. 
The tethered agonist experiments have been successfully applied in mapping the 
nAChR binding site and yielded decent results in the MOD-1 receptor. By rational design 
of the tethered agonists in combination with the powerful unnatural amino acid 
mutagenesis methodology, the tethered agonist approach will be very useful in studying 
the ligand-binding sites. Understanding the details of the ligand-binding sites will provide 
guidance for drug designs.  
 
 
5.5 Methods 
5.5.1 Electrophysiology 
 Electrophysiological recordings were made 24–72 hours after injection. Whole-
cell currents from stage VI oocytes of Xenopus laevis were measured in standard two-
electrode voltage clamp mode using the OpusXpressTM 6000A (Axon Instruments, Union 
City, California). Microelectrodes were filled with 3M KCl and the resistances were 
between 0.5 and 2 MΩ. Oocytes were continuously perfused with calcium-free ND96 or 
ND96 bath solution at flow rates of 1 ml/min, 4 ml/min during drug application and 3 
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ml/ml during wash. The holding potential was -60 mV. Data were sampled at 125 Hz and 
filtered at 50 Hz. Drug applications were 15 s. Serotonin was purchased from 
Sigma/Aldrich and all drugs were prepared in calcium-free ND96 or ND96 solution. 
Dose-response data were obtained from 3 to 5 oocytes and data were reported as mean ± 
standard error. Curves were fit to the Hill equation, I/Imax = 1/[1 + (EC50/[A])nH], where I 
is the current for agonist concentration [A], Imax is the maximum current, EC50 is the 
concentration to elicit a half-maximum response, and nH is the Hill coefficient.  
 
5.5.2 Incorporation of Unnatural Amino Acids by in vivo Nonsense Suppression 
Methods 
For suppression experiments, 25 ng of tRNA and 10 ng of mRNA were co-
injected in a total volume of 50 nL per oocyte. Immediately before the microinjection, the 
NVOC-aminoacyl-tRNA was deprotected by photolysis. The ligation of aminoacyl-dCA 
to tRNA and gene construction of suppressor tRNA have been described previously. The 
MOD-1 gene was subcloned into the plasmid pBlueScript. The MOD-1 TAG mutants 
were made by the QuickchangeTM site-directed mutagenesis method and were monitored 
by DNA sequencing. Plasmid DNAs were linearized with KpnI, and mRNA was 
transcribed using the Ambion T3 mMESSAGE mMACHINE kit.  
 For wild type and conventional mutation experiments, only 5 ng mRNA was 
injected into oocytes in a 50 nL volume per cell with the same following procedure as 
described above.  
 The tethered agonists used in the experiments were obtained from Lintong Li and 
E. James Petersson. The preparations were described elsewhere.5-7  
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